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ABSTRACT 
 
 Radiation injury in the esophagus occurs with high frequency from the treatment of 
non-small cell lung cancer (NSCLC). Radiation esophagitis is an acute normal tissue toxicity that 
negatively affects treatment efficacy by limiting dose and potentially interrupting radiation 
therapy. Clinical quantification of this toxicity is typically achieved by utilizing physician grading 
scales, assigning complication severity on an ordinal scale of symptom presentation and/or 
physician chosen interventions. These criteria are subjective in nature, both from the physician 
assigning the grade and the patient reporting the symptom. Furthermore, radiation therapy 
planning guidelines for the esophagus are derived from toxicity prediction models utilizing 
these subjective grading scores as complication endpoints. Not only does this schema of 
toxicity analysis leads to a lack of consistency between models from different study 
populations, and thereby radiation therapy planning recommendations for the esophagus, but 
inherent patient radiosensitivity is not considered, leading to suboptimal treatment regimens. 
The purpose of this work was to investigate radiation injury in the esophagus by first 
developing in-vivo imaging biomarkers of radiation-response in the esophagus using 4-
dimensional computed tomography (4DCT) and 18fluorodeoxyglucose positron emission 
tomography (FDG-PET), separately. These imaging biomarkers were then compare with 
radiation esophagitis grade, using traditional and machine learning techniques, and shown to 
objectively quantify esophageal radiation toxicity. Metrics describing the esophageal radiation 
response from either imaging modality were strong classifiers of radiation esophagitis grade. 
Multivariate models to predict maximum esophagitis treatment grade (4DCT), and esophagitis 
symptom progression (FDG-PET) were developed and had strong performance for both 
scenarios.  
These imaging biomarkers were then used to comprehensively investigate the influence 
of dose-geometry and radiation type (photon or proton) on esophageal response. Using these 
radiation-response biomarkers in esophageal dose-response analysis, dose metrics with spatial 
information of esophageal dose coverage, (e.g. dose to a subregion of the esophagus with 
specific percent cross-sectional area coverage), as well as without spatial information, 
(traditional dose-volume histogram), was analyzed separately using machine learning methods. 
No detectable difference in response was observed when comparing dose metrics with and 
vi 
 
without spatial information. Statistical analysis showed no significant difference (p<0.05) in 
biomarker value when comparing patient populations of different radiation type (intensity-
modulated photon radiation therapy versus passive-scatter proton therapy).  
Inherent patient radiation sensitivity was investigated using esophageal expansion and 
delivered dose to the corresponding esophageal subregion. Cluster analysis was used to group 
patient patients based on their maximum expansion and delivered dose to the analyzed 
subregion of the esophagus. Patients clustered with proportionally higher expansion per 
delivered dose were considered radiosensitive. These results were then applied to NTCP toxicity 
modelling by using patient radiosensitivity cluster membership as a predictor variable. Models 
with the radiosensitive predictor outperformed models not including the cluster membership 
variable for prediction of grade 3 esophagitis.    
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Chapter 1 
 
Introduction 
 
 
Radiation Esophagitis is a prevalent normal tissue toxicity with tremendous negative 
impact on quality of life for patients with non-small-cell lung cancer (NSCLC) treated with 
radiation therapy.1 Typically, radiation esophagitis presents as an acute toxicity during 
radiotherapy for NSCLC, with occurrence rates of approximately 25% for concurrent 
chemoradiation therapy.2-6 Mild esophagitis symptoms can be treated or managed with proton 
pump inhibitors, local anesthetics, oral analgesics, narcotics, and alteration of diet.7,8 If 
symptoms become severe enough, intravenous fluids, total parenteral nutrition, or 
percutaneous endoscopic gastrostomy (PEG) tube, with or without possible hospitalization may 
be prescribed. These interventions represent large financial burden for the patient and time-
consuming resources for the hospital or supporting care facility.    
In addition to the negative impact on patient quality of life, acute radiation esophagitis 
can affect treatment outcomes. Normal esophageal tissue dose, out of concern for radiation 
esophagitis complications, can limit the amount of prescribed dose to the malignant tumor 
volume. It is common that the tumor volume is located near the esophagus, and even with 
advances in treatment planning and delivery (conformation) of dose, the esophagus routinely 
receives sufficient radiation to induce toxicity. Furthermore, if radiation esophagitis becomes 
severe enough it can result in treatment interruption. On-time completion of radiation therapy 
has been identified as the most crucial factor in treatment outcome for unresectable lung 
cancer.4   
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Several strategies to prevent radiation esophagitis have been studied. One such strategy 
is the use of radioprotectors such as amifostine. While tumor control is increased by adding 
concurrent chemotherapy to radiation therapy, this also increases the risk of esophagitis. The 
concept behind utilizing radioprotectors is to ameliorate the esophagitis symptoms while 
reaping the tumor control benefit of concurrent chemoradiation therapy, thereby increasing the 
therapeutic ratio. However, the use of radioprotectors with chemoradiation therapy has had 
mixed results. Several small trials of radiation therapy combined with the use of radioprotectors, 
most commonly amifostine, have showed a reduction in radiation esophagitis incidence.9-13 
Conversely, a large randomized trial of amifostine did not show a significant reduction in the 
occurrence of severe radiation esophagitis.14    
The most directly controllable clinical factors associated with radiation esophagitis are 
the dose-constraints to the esophagus during the radiation treatment planning process. For 
example, the radiation therapy oncology group (RTOG) 0617 trial was designed with a 
recommended mean esophageal dose (MED) to be less than 34 Gy, as well as the volume of 
esophagus receiving at least 60 Gy (V60) to be recorded.2,15 These dose-constraints leave a 
wide margin of possible dose-volume configurations available for radiation treatment planning. 
Furthermore, several studies have investigated increased restriction of esophageal dose in the 
treatment planning process, while maintaining tumor coverage, showing potential optimization 
of radiotherapy plans for minimizing esophagitis incidence. However, sparing of the esophagus 
can cause increase in radiation dose to other normal tissues, such as the lung, heart and spinal 
cord, potentially exceeding the dose-constraints for these organs.16-18   
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Radiation esophagitis is commonly quantified on an ordinal scale with increasing score 
or value, corresponding to increasing esophagitis symptom severity. One frequently used 
esophagitis grading system is the Common Terminology Criteria for Adverse Events (CTCAE).19 
The esophagitis severity quantification of CTCAE 3.0 is given in Table 1.1. The most recent 
version of CTCAE, version 4.0, removed the intravenous fluid criterion for grade 
determination.20  
 
Table 1.1: CTCAE 3.0 esophagitis grading system. 
Grade Criteria 
1 
Asymptomatic pathologic, radiographic, or endoscopic 
findings only 
2 
Symptomatic; altered eating or swallowing (altered dietary 
habits, oral supplements); intravenous fluids indicated for less 
than 24 hours 
3 
Symptomatic and severely altered eating or swallowing 
(inadequate oral caloric or fluid intake); intravenous fluids, 
tube feedings, or total parenteral nutrition indicated for more 
than 24 hours 
4 Life-threatening consequences 
5 Death 
 
 
There are numerous drawbacks to this methodology of quantifying esophagitis severity. 
The subjective nature of grades themselves creates uncertainty in the scoring process; the 
grades are determined from physician chosen interventions based on patient reported 
symptoms, with variation between both the patient reporting the symptoms and the physician 
prescribing the intervention. Another drawback to grading of esophagitis severity is the lack of 
4 
 
localization of the toxic region of the esophagus. Under grading schema, the whole organ must 
be treated as toxic (e.g. grade 3) or asymptomatic (e.g. grade 0). This ignores the possibility that 
toxicity is located in a sub volume of the esophagus, which should be the primary region of 
study for esophagitis amelioration and prevention. One important drawback specifically with 
grading criteria and radiation therapy is the desire to understand cause and effect associated 
with the radiation dose. Esophagitis symptoms can be caused by conditions unrelated to 
radiation therapy such as gastroesophageal reflux or esophageal infection. Therefore, it would 
be ideal to isolate toxicity solely from radiation when investigating esophageal toxicity.     
 The primary objective of investigating esophageal toxicity is to prevent complications 
from occurring, rather than minimizing symptom severity after presentation. The development 
of toxicity prediction models, commonly referred to as normal tissue complication probability 
(NTCP) models, which are based on previous clinical experience, and then applying these 
models to future patients with the goal of reducing toxicity incidence. Common practice is to 
create multivariate logistic regression models with many clinical and dosimetric parameters as 
model predictors, and esophagitis grade as the dichotomized endpoint. In statistical learning, 
this is deemed a classification problem, with esophagitis grade being the item sought to be 
classified.   
The literature contains copious amounts of NTCP studies for the esophagus.2,3,5,6 
Comparison of many NTCP studies shows a lack of agreement between specific dosimetric 
predictors and esophagitis complication. Furthermore, a commonality exists where NTCP 
models fit the training dataset well, but lack generalizability to external datasets.2,3,21-24 This is 
a common pitfall in prediction modelling, where over fitting the training data leads to poor 
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predictive model performance on external datasets. As previously stated, the esophagitis 
endpoint itself has associated uncertainty, which will affect any toxicity model’s predictive 
performance.  
Another source of uncertainty in the NTCP modelling process includes variability of 
esophagus positioning on the planning CT, which can affect dosimetric accuracy. In one study, 
variability of esophagus position in Cartesian space was measured from different phases of 
4DCT for 29 patients. Motion of the central axis of the esophagus was as extreme as 4mm in 
the medial/lateral direction.25 Another study found esophageal motion as high as 13.8mm in 
the cranio-caudal direction.26 A study of 236 lung cancer patients showed correcting the 
esophagus dose-volume histogram (DVH) for anatomical uncertainties improved correlation of 
DVH dose metrics to esophagitis grade.27 
Another explanation for the underwhelming performance of esophagitis prediction 
models is the lack of consideration for inherent patient radiosensitivity. If we consider two 
patients receiving similar radiation therapy dose to the esophagus, it is quite possible one 
patient may develop severe radiation esophagitis, while the other patient may be 
asymptomatic. If the NTCP model does not have some means to quantify this difference in 
radiosensitivity, then model uncertainty has been increased as both patients have similar model 
predictors, but different classification endpoints. Genomic data has recently been introduced 
into the NTCP modelling process in an attempt to account for radiosensitivity.28-31 However, 
validating genetic predisposition to radiation toxicity using esophagitis grade is still beholden 
to the uncertainty of the subjective complication endpoint. 
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The inclusion of spatial dose terms, or dose-geometry, can potentially determine if 
partial sparing of the esophagus is achievable. Most studies use dose-volume metrics such as 
volume of esophagus receiving at least a particular dose, but some studies have included dose 
metrics that yield spatial information of dose conformity instead of simply using a gross 
average or threshold of dose-volume.32-35 One example of spatial dose metrics is the length of 
the esophagus receiving a particular dose with a specific percent of axial coverage across the 
cross-sectional area of the imaged slice of the esophagus.  
Previously, optimization of treatment planning for reduced esophagus dose showed 
feasibility for external beam radiation therapy of lung malignancies.17 In this study, 
retrospective analysis of patients that exhibited grade 3 esophagitis during treatment showed 
sizeable reductions in dose-volume above 50 Gy were achievable on re-planning with heavy 
constraint on the esophagus, with preservation of tumor dose coverage.  Therefore, there exists 
clinical utility and viability in optimizing dose-geometry of normal esophagus. While 
investigation of partial sparing has had some success in other normal tissues, such as the 
salivary glands or bone marrow, up to this point there is no clear influence of dose-geometry 
and esophageal toxicity.32-39 It is possible that any dose-geometry effect of toxicity in the 
esophagus, if it exists, could be undetectable with an endpoint such as esophagitis grade, and 
may require a more sensitive measure of toxicity. Moreover, if partial sparing is achievable in 
the esophagus, lack of utilizing dose-geometry could be one explanation for the variability in 
esophagitis toxicity prediction models.  
Esophageal expansion, or swelling, is an inflammatory response that is discernible on CT 
imaging.40 Another study has shown radiation esophagitis can be visualized on 4DCT as an in-
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vivo technique throughout the course of radiotherapy.41 Furthermore, this study showed that 
the change in the esophagus contour over the course of radiation therapy can be used as a 
surrogate for esophageal expansion. In addition, the average relative expansion of the 
esophagus was significantly different between patients with grade 0 and grade 3 esophagitis. 
Therefore, the esophageal expansion response may be a reliable quantification of radiation 
response in the esophagus.  
 18Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a functional imaging 
technique that uses glucose metabolism as a surrogate for tissue inflammation. Primarily used 
in the radiation oncology setting for tumor detection, delineation, and treatment assessment, 
FDG-PET has been shown to quantify radiation-induced lung toxicity.42-44 The slope of FDG 
uptake and lung dose has been shown to correlate to radiation pneumonitis grade for both 
lung and esophageal cancers in external beam radiation therapy.45-49 Another study examined 
FDG uptake correlation to esophagitis grade using FDG-PET imaging at follow up from 
radiation therapy.50 This study showed the addition of FDG uptake into a NTCP model 
increased prediction of grade 2 and higher esophagitis.   
 The purpose of this work is to comprehensively enhance understanding of radiation 
injury in the esophagus, which can thereby optimize radiation therapy treatment outcomes and 
improve patient quality of life. Esophageal expansion and inflammation, from 4DCT and FDG-
PET respectively, will be investigated as radiation response and toxicity measures. This is to 
address the uncertainty inherent in current toxicity grading systems. Any improvement in 
toxicity prediction models will be explored and then used to investigate dose-response in the 
esophagus, with the previously mentioned prediction model sources of uncertainty addressed. 
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This will be applied in both broad dose-response models, and a spatially localized response 
analysis to investigate any influence in esophageal dose-geometry and toxicity, to determine if 
partial sparing can be achieved in the esophagus. Any influence of radiation type and 
esophageal response will also be examined. Potentially, expansion and inflammation can yield 
information about patient-specific response to radiation, and therefore inherent patient 
radiosensitivity. The efficacy of the expansion mechanism to identify radiosensitive patients, and 
this information’s impact on dose-response and radiation injury in the esophagus will be 
investigated. 
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Chapter 2 
 
Central Hypothesis and Specific Aims 
 
 
2.1 Central Hypothesis 
 
The overall objective of this project is to identify objective, in-vivo biomarkers of 
esophageal radiation-response as quantifications of toxicity and to utilize these metrics to 
improve prediction modelling of radiation injury in the esophagus, as well as to determine if 
dose-response in the esophagus is dependent on dose-geometry or radiation therapy modality, 
and to investigate the use of these radiation-response measures as patient-specific biomarkers 
of radiosensitivity.   
The central hypothesis is that objective metrics quantified from 4DCT and FDG-PET 
imaging, during radiation therapy, are biomarkers of radiation-response in the esophagus, 
which can be used to improve understanding of radiation injury in the esophagus.  
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2.2 Specific Aims 
To test the central hypothesis, the following specific aims were developed and 
investigated: 
Specific Aim 1: Analysis of CT-based esophageal expansion to quantify radiation-response in 
the esophagus during radiation therapy.  
Hypothesis: CT-based esophageal expansion is a biomarker of radiation-response that can 
quantify radiation injury in the esophagus and can be used to improve outcome modelling of 
radiation-induced esophagitis.  
 
To test the hypothesis, the following projects were conducted: 
Project 1.1: Analyze whether CT-based expansion is a quantification of esophgeal radiation 
toxicity  
Project 1.2: Analyze the utility of CT-based expansion metrics in outcome modelling 
 
Specific Aim 2: Analysis of FDG-PET to quantify esophageal radiation-response in the 
esophagus during radiation therapy.  
Hypothesis: FDG-PET uptake is a biomarker of radiation-response that can quantify radiation 
injury in the esophagus and can be used to predict esophagitis symptom progression during 
radiation therapy.  
 
 
 
11 
 
To test the hypothesis, the following projects were conducted: 
Project 2.1: Analyze whether FDG uptake in the esophagus is a quantification of esophageal 
radiation toxicity 
Project 2.2: Analyze whether FDG uptake in the esophagus can predict esophagitis symptom 
progression during radiation therapy 
 
Specific Aim 3: Analysis of esophageal dose-response using radiation-response biomarkers. 
Hypothesis: Esophageal expansion will identify if dose-geometry or radiation type contributes 
to radiation injury in the esophagus, and that expansion can be used to quantify patient-
specific radiosensitivity.   
 
To test the hypothesis, the following projects were conducted: 
Project 3.1: Analyze whether dose-geometry influences esophageal radiation response. 
Project 3.2: Analyze whether there exists any difference in esophageal radiation response 
between photon-based intensity modulated radiation therapy (IMRT) and passive-scatter 
proton therapy (PSPT). 
Project 3.3: Analyze whether esophageal expansion can quantify patient-specific 
radiosensitivity and determine if this knowledge can improve understanding of esophageal 
dose-response. 
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The outcomes of this work show esophageal expansion and normalized FDG uptake are 
objective, in-vivo radiation response measures that can be used as surrogates for radiation 
injury in the esophagus. Moreover, when utilized as endpoints, these biomarkers improve 
toxicity prediction modelling in the esophagus. Finally, the expansion biomarker and 
corresponding dose show inherent patient-specific radiosensitivity. This work will have positive 
impact by developing and applying in-vivo toxicity biomarkers that can potentially enhance 
personalization of radiation therapy, leading to improved treatment outcomes and increase 
patient quality of life.  
 
 
2.3 Dissertation Structure 
 
 The remaining chapters of the dissertation are organized to address each specific aim in 
chronological order. Chapters 3 and 4 together address specific aim 1, by first developing a 
computational method to calculate esophageal expansion and correlating this measure of 
radiation-response to esophageal toxicity (project 1.1), and then examining predictive model 
performance with expansion as an endpoint (project 1.2). Chapter 5 addresses specific aim 2 by 
calculating normalized FDG uptake and correlating this measure of response to esophageal 
toxicity (project 2.1), and then using this biomarker to predict symptom progression (project 
2.2).  
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Chapter 6, 7, and 8 address specific aim 3. Chapter 6 presents the investigation of dose-
geometry and its relationship with esophageal expansion (project 3.1). The work in Chapter 7 
analyzes esophageal response from different therapeutic radiation types (proton or photon 
radiation, project 3.2). Chapter 8 describes the use of the objective metrics to identify patient-
specific radiosensitivity, and then apply these radiosensitivity assays to improve prediction 
modelling of radiation-induced esophagitis (project 3.3).  
Chapter 9 presents a summary and the conclusions of this work. This chapter also 
presents directions for future work based on the results of this dissertation.  
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Chapter 3 
 
Esophageal Expansion Quantified from 4-Dimensional Computed 
Tomography as a Measure of Esophageal Radiation Injury 
 
 
 
 The work in this chapter investigates esophageal expansion, as quantified from 4DCT, as 
a radiation-response and toxicity measure for radiation injury in the esophagus. Robust metrics 
of esophageal expansion are derived for classification of toxicity. These expansion metrics are 
then shown to be robust biomarkers of esophageal radiation-response and esophageal toxicity, 
by statistical analysis with physician scored radiation esophagitis grade. This chapter comprises 
project 1.1, of specific aim 1. 
 
A substantial portion of this chapter is based on the following publication:  
Niedzielski JS, Yang J, Stingo F, Martel MK, Mohan R, Gomez DR, Briere TM, Liao Z, Court LE. 
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3.1 Methods and Materials 
3.1.1 Patient Population 
For the work in this chapter, 94 patients were selected from a prospective clinical trial of 
radiation therapy using either IMRT or passive-scatter proton therapy (PSPT) for stage III NSCLC 
at University of Texas-MD Anderson Cancer Center, treated with intensity-modulated radiation 
therapy and concurrent chemotherapy (paclitaxel and carboplatin), with tumor prescription 
doses of 60 (n=4), 66 (n=28), or 74 (n=53) Gy in 2-Gy fractions over 6-8 weeks. Due to sample 
size we utilized the patients from the IMRT arm of this trial. Of the 94 study patients, 85 patients 
had weekly 4DCT imaging, while a total of 9 patients with weekly breath hold CT (BHCT) 
imaging. Three patients were excluded from the original 97 IMRT patient cohort due to poor 
image quality. 
These patients had prospective weekly esophagitis scoring by the radiation oncologist 
according to Common Terminology Criteria for Adverse Events version (CTCAE) 3.0.19 The 
grading scale can be summarized as: grade 0, no esophagitis; grade 1, asymptomatic with only 
clinical or diagnostic observations; grade 2, symptomatic with altered eating/swallowing and 
oral supplements; grade 3, severely altered eating/swallowing with tube feeding, total 
peritoneal nutrition, or hospitalization; grade 4, life-threatening consequences; and grade 5 is 
death.20  The clinical esophagitis symptom management was: liquid narcotic medication, topical 
anesthetics, and antacid medication for grade 2, and IV fluids with possible feeding tube for 
grade 3. The distribution of maximum esophagitis grades during treatment was: 24 were grade 
0, 45 were grade 2, and 16 were grade 3. There were no grade 1 patients in this study, as 
asymptomatic diagnostic assessment of esophagitis was not conducted. This study was 
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approved by the University of Texas-MD Anderson Cancer Center Institutional Review Board 
and was compliant with HIPAA regulations. 
CT scans were acquired on General Electric Lightspeed Discovery ST or Lightspeed RT16 (GE 
Healthcare, Waukesha, WI) or Philips Brilliance 64 (Philips Healthcare, Bothell, WA) CT scanners 
operated at 120 kV. Voxel dimensions were 0.98x0.98x2.50 mm in the right-left direction, 
anterior-posterior, and superior-inferior direction, respectively, with a 512×512 pixel area. 
Treatment planning for all patients whose data were used in our study was conducted using the 
Pinnacle treatment planning system (Phillips Healthcare), including segmentation. Esophageal 
contours were segmented in Pinnacle version 9.8 in the axial plane, from the cricoid cartilage to 
the gastroesophageal junction by an experienced treatment planner and verified by the 
radiation oncologist.  
 
3.1.2 Computational Framework and Jacobian Map Algorithm 
The computational framework used to calculate esophageal expansion on the treatment 
plan for any treatment week can be summarized in 3 steps: segmentation, deformable image 
registration, and the Jacobian map algorithm. A general overview of this process is shown in 
Figure 3.1. Esophagus contours were delineated on the planning image. Next, deformable 
registration was performed between the plan and weekly CT images to obtain deformation 
vector fields, and propagate segmentation to weekly CT images. Finally, the algorithm uses the 
deformation vector fields, planning, and weekly contours to calculate the local esophageal 
volume change with correction due to anatomical variability as an average of slices of the 
esophagus along the cranio-caudal axis.  
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Figure 3.1 General overview of the computational framework to calculate esophageal 
expansion. 
 
A demons algorithm was used to perform deformable image registration from the 
planning CT to the weekly CT image set; this algorithm was validated for thoracic patients.7,8 
Let 𝒅𝒖 = (𝑑𝑥, 𝑑𝑦, 𝑑𝑧) denote the deformation vector pointing from voxel 𝒖 = (𝑥, 𝑦, 𝑧) in the 
planning image to the weekly CT image voxel 𝒖′ = (𝑥′, 𝑦′, 𝑧′). The voxel mapping from the plan 
to the weekly image becomes: 
 𝒖′(𝑥′, 𝑦′, 𝑧′) =  𝒖(𝑥, 𝑦, 𝑧) + 𝒅𝒖(𝑑𝑥, 𝑑𝑦, 𝑑𝑧)                              (3.1) 
The Jacobian Map is calculated by taking the determinant of the Jacobian of the 
transformation defined in equation 3.1, using 𝒅𝒖 for every voxel in the esophagus. The Jacobian 
represents the local voxel-volume change, and thus voxel esophageal expansion, from the 
deformable registration of the plan to the weekly CT imageset.52-55 A Jacobian map of 1.0, >1.0, 
18 
 
and <1.0, represents no volume change, relative expansion, and relative shrinkage, respectively, 
for the voxel anatomy from the planning to the corresponding weekly CT.  
For each of the 85 patients, after deforming the planning exhale phase all the other plan 
phases, and all weekly 4DCT phases, the deformation vector fields were used to calculate the 
corresponding Jacobians. The Jacobians were then averaged at each axial slice of the 
esophagus and esophageal expansion metrics were calculated.  
To validate this computational framework, a digital phantom representing esophageal 
expansion was developed consisting of a pair of CT image sets containing: (1) a uniform 
cylindrical volume of tissue equivalent CT numbers, and (2) another cylindrical volume of tissue 
equivalent CT numbers, but regions of differing volume in the axial plane to represent 
expansion in the esophagus.  Figure 3.2 illustrates this phantom, in which the expansion image 
has a region of the same area as the uniform image and regions of twice and thrice the original 
uniform area (‘2A’ and ‘3A’ in Figure 3.2, respectively), as well as regions of changing cross-
sectional area (white region in ‘target image’ of Figure 3.2). The observed axial expansion is 
tested against the ground truth of relative volume change, which is known for a given slice. 
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Figure 3.2: Representation of the digital phantom image pair that is used to validate the 
jacobian map algorithm used to quantify esophageal expansion. The plan image of uniform 
cross-sectional area is deformed to a target image that has the axial area known for each slice 
in the esophagus, along the superior-inferior direction. The deformation vector field from the 
deformable image registration is entered into the Jacobian map algorithm and relative volume 
change for each axial slice of the phantom esophagus is calculated. Uncertainty in the Jacobian 
map calculation is then assessed using the known and measured axial volume values.  
 
3.1.3 Anatomic Volume Variability and Correction Methods 
Physiological effects that skew esophageal volume calculations are numerous, including 
motility of the esophagus, dilation, swallowing during CT acquisition, and esophageal air. The 
presence of air in the esophagus is particularly challenging. Because deformable image 
registration uses CT number as a measure of image similarity, any 2 images in which 
esophageal air is present in one image but not the other have a high chance to cause 
deformable registration error in this region, propagating into the Jacobian calculation. The 
uncertainty caused by esophageal air makes expansion quantification on the voxel-level 
unreliable. However, quantifying expansion for an axial slice is possible and a method to correct 
uncertainty associated with esophageal air can be accomplished by utilizing the axial anatomy. 
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To reduce errors caused by air content, an “air content correction factor” can be 
calculated for each axial slice as the relative ratio of tissue in the esophagus on the planning 
image to that in the weekly image: 
      𝐽𝑀𝑎𝑖𝑟 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝐽𝑀𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 ∗ 𝜓,         𝑤ℎ𝑒𝑟𝑒 𝜓 =
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑤𝑒𝑒𝑘𝑙𝑦 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑒𝑠𝑜𝑝ℎ𝑎𝑔𝑒𝑎𝑙 𝑡𝑖𝑠𝑠𝑢𝑒
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑝𝑙𝑎𝑛 𝑒𝑠𝑜𝑝ℎ𝑎𝑔𝑒𝑎𝑙 𝑡𝑖𝑠𝑠𝑢𝑒
     (3.2)   
The quantity 𝐽𝑀𝑎𝑖𝑟 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑  is the axial-averaged Jacobians corrected for air content in both 
planning and weekly images, and  𝐽𝑀𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑   is the originally calculated Jacobian. The quantity 
ψ is the air content correction factor, computed at each axial slice of the esophagus.  
Miscalculations of local volume change caused by intra-scan transient effects are 
minimized in 2 ways. The first method corrects transient effects on the plan image by 
deforming the exhale phase to all phases of the planning image and then computing an axial-
Jacobian-averaged from all the phase deformations, which yields the plan normalization 
correction factor: 
𝐽𝑀𝑝𝑙𝑎𝑛 𝑛𝑜𝑟𝑚 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =
<𝐽𝑀𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑>
Ф
,       𝑤ℎ𝑒𝑟𝑒 Ф = < 𝐽𝑀𝑒𝑥ℎ𝑎𝑙𝑒 𝑝ℎ𝑎𝑠𝑒 𝑡𝑜 𝑝𝑙𝑎𝑛 𝑝ℎ𝑎𝑠𝑒𝑠 >                  (3.3) 
The mean axial-averaged Jacobian from the exhale phase to the planning phase deformations 
is the plan normalization correction factor, denoted Ф. Dividing the Jacobian of the planning 
exhale phase to all weekly phases, denoted < 𝐽𝑀𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 >, by Ф yields the Jacobian corrected 
for transient effects 𝐽𝑀𝑝𝑙𝑎𝑛 𝑛𝑜𝑟𝑚 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑. Random esophageal motion and swallowing during CT 
acquisition are transient anatomical effects that may reduce the accuracy of the Jacobian 
calculation. 
The second method reduces contributions to volume change from non-treatment-
related sources on the weekly CT. Similar to the first correction, we utilize all phases of the 
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weekly images to create a mean axial-averaged Jacobian. The mean of the plan exhale phase 
Jacobian to all weekly phases averaged at each axial segment of the esophagus, applying both 
anatomic variability correction factors, becomes: 
              𝐽𝑀𝐹𝑖𝑛𝑎𝑙 = < 𝐽𝑀𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 > =  
<𝐽𝑀𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑>
Ф
∗ 𝜓                           (3.4) 
where < 𝐽𝑀𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 >  is the weekly 4DCT phased-averaged axial Jacobian with all correction 
factors applied, resulting in  𝐽𝑀𝐹𝑖𝑛𝑎𝑙, which is the weekly Jacobian used to derive all metrics of 
esophageal expansion for the given treatment week.  
To test the correction methodology and quantify uncertainties, the Jacobian from 
planning to first treatment week is used to measure inter-CT scan variability without radiation-
response, because insufficient time or dose has been delivered to induce esophageal 
expansion. The effect of anatomic variability correction is quantified by 2 metrics, with and 
without anatomic corrections. The first metric is the absolute difference between the axial 
Jacobians and a value of 1.0. Jacobian calculation without any radiation-induced expansion 
should show values close to 1.0. The second metric is the full-width half-maximum (FWHM) of 
the distribution of axial Jacobian values for all phases of the first week; accurate deformations 
have normal distributions of Jacobians centered near 1.0, with small FWHM values. 
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3.1.4 Esophageal Expansion Metrics 
Various metrics were created to quantify esophageal swelling, including the following: 
 Mean axial esophageal expansion (MeanExp) 
 Maximum axial esophageal expansion (MaxExp) 
 Esophageal length ≥ specified percent of axial expansion (LenExp), ranging from 20% to 
100% in 10% increments (LenExp20% for 20% expansion) 
 Peak esophageal expansion of 3, 5, and 7 axial slices of the esophagus (PeakExp3 for 3-
slice peak expansion) 
 Percentile of esophageal expansion (PerExp), ranging from sixtieth to ninetieth in 
increments of 10, as well as ninety-eighth (PerExp60% for sixtieth percentile of 
expansion) 
 
These quantifications allowed us to examine expansion using the average (MeanExp), 
maximum (MaxExp), spatial-length dependence (LenExp), and volume dependence of the 
expansion (PerExp). The MaxExp3-MaxExp7 metrics are meant to overcome uncertainties in 
quantifying MaxExp1 (which measures only a single axial response point). LenExp represents the 
physical esophageal length that increases in volume at least a given percentage. PerExp 
represents the expansion value for which the given percentiles of all other expansion values are 
below. An axial comparison of esophagi before and during treatment is shown in Figure 3.3. 
The temporal relationship between expansion and esophagitis grade was also investigated by 
comparing the timing of maximal expansion and esophagitis grade. 
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Figure 3.3: Example of axial expansion of esophagus as relative change from planning (a,c) to 
treatment week 6 (b,d). Top patient (a,b) has maximum grade 0 esophagitis and no change in 
esophagus volume (esophagus is outlines in red). Bottom patient (c,d) has maximum grade 3 
esophagitis and considerable expansion (esophagus is outlines in blue).  
 
3.1.5 Expansion & Toxicity Analysis 
An analysis was conducted to determine any relationship between the expansion 
metrics and radiation esophagitis severity. The treatment week with maximal expansion was 
compared to the patient’s maximum esophagitis grade during treatment. Normal tissue 
complication probability (NTCP) from univariate logistic regression and Spearman rank 
correlation coefficients were calculated for expansion metrics with grade 2 and grade 3 
esophagitis endpoints, with the metric value with 50% probability of grade 2 and grade 3 
esophagitis calculated for each expansion metric. P-values were calculated using the likelihood 
ratio chi-square test. The Benjamini-Hochberg false discovery rate procedure was applied to all 
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p-values. Receiver operating characteristic (ROC) analysis was used to quantify the performance 
of each expansion metric in classifying esophagitis. For all analyses, p<0.05 after application of 
the Benjamini-Hochberg procedure was considered statistically significant. All statistical 
analyses were carried out in Matlab version 7.9 or version 8.2 (Mathworks, Natick, MA). 
 
3.1.6 Esophageal Expansion & Breath Hold CT 
To determine the suitability of this expansion calculation methodology with breath hold 
CTs (BHCT), all 9 patients from the clinical trial patient pool with weekly BHCT imaging during 
treatment were analyzed. Of these nine patients, 5 had both weekly 4DCT and BHCT imaging 
for a single treatment week, in addition to a plan 4DCT image set. This allowed a direct 
comparison of esophageal expansion calculated from either 4DCT or BHCT imagining. The 
expansion computational framework was tested on these BHCT patients in the same manner as 
the weekly 4DCT patient cohort.  
The planned BHCT was deformed to all 3 BHCTs taken during the planning process, as 
well as 3 BHCTs acquired for every treatment week. The expansion metrics were then calculated 
for every treatment week with an available serial CT. In addition, the variance of the esophageal 
volume was calculated for the plan BHCT to the other BHCTs taken on the planning date and 
the serial BHCTs.  The same methodology of correcting esophageal anatomic variability used 
for the patients with primary 4DCT imaging was applied to BHCT patients, with multiple BH 
scans used in place of the phases of the 4DCT image set.     
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3.2 Results 
3.2.1 Validation of Jacobian Map Algorithm and Anatomic Volume Variability  
The result from the digital phantom test of the Jacobian map algorithm is shown in 
Figure 3.4. The top pane of Figure 3.4 shows good agreement between calculated and known 
anatomical volume change with the pattern of volume change along the superior-inferior 
direction of the esophagus, as originally shown in Figure 3.2. Furthermore, this test shows that 
uncertainty in the Jacobian Map algorithm correctly calculating the relative volume change of 
the esophagus is below 5.0% for any given esophageal slice. 
Next, the anatomical variability correction was tested on 75 of the 85 study patients. 
Since treatment week 1 images were not available for 10 of these 85 patients, these patients 
were excluded from the anatomic correction analysis. The top panel in Figure 3.5 shows the 
axial Jacobian profile along the esophagus for the planning exhale phase deformed to the 
planning image for one patient. The volume variability of each phase-Jacobian can be observed 
on the planning image, and variability was reduced by taking the mean Jacobian of all phases 
from each axial location (dashed black line). The mean axial Jacobian was close to 1.0 for all 
points along the esophageal-length, representing an accurate calculation. A similar trend was 
observed with the Jacobian profiles for the first treatment.  
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Figure 3.4: Results of the digital phantom test to validate relative volume change clouted using 
the Jacobian map algorithm along the superior-inferior length of the phantom. The relative 
expansion calculated from the Jacobian map algorithm is shown at the top. The percent error in 
calculated versus known axial volume is shown at the bottom. 
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Figure 3.5: (Top) Axial averaged Jacobian map for all phases and mean Jacobian (black dashed 
line) of all phases for the planning 4DCT image set for one patient. T00 represents the 
inspiration phase and T50 the exhale phase. (Middle) Relative axial cross-sectional area of air 
content for the planning (solid black line) and week 1 (dashed red line) T50 phases for one 
patient. (Bottom) Axial averaged Jacobian map of the week 1 T50 phase, uncorrected (black 
line) and with full anatomic correction (blue line), for one patient.  
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 The middle panel in Figure 3.5 shows the relative air content in plan and week 1 exhale 
images for the same patient. A large difference in air content occurred around slice 25, causing 
Jacobian miscalculation at the corresponding slice, shown in the bottom panel of Figure 3.5 
(solid black line). By applying the anatomic corrections, we obtained a more accurate Jacobian 
value (solid blue line, bottom panel).  
Figure 3.6a,b shows the plan to week1 Jacobian distributions with and without anatomic 
variability correction for one patient. The distribution had a long asymmetric tail to small 
Jacobians before correction and a more symmetric distribution with smaller FWHM values and a 
peak centered closer to 1.0 after correction.  
Figure 3.6c is a boxplot showing the distribution of FWHM values for the plan to week1 
Jacobian distributions before and after anatomic correction was applied. Applying the anatomic 
correction reduced the FWHM values of the Jacobian distributions by 10.3% (±5.6%), average 
percent-difference with standard deviation in brackets. For all axial slices, the mean absolute 
percent-differences between the Jacobians and a value of 1.0 ranged from 13.3% (±5.4%) to 
9.2% (±5.6%) after the anatomic correction were applied.  
 
3.2.2 Expansion Metrics and Esophagitis Severity 
Expansion metric distributions were grouped according to esophagitis grade (Figure 
3.7a-c). This analysis illustrated a strong relationship between increased expansion values and 
increased esophagitis grades; the relationship was most pronounced for the MaxExp-based 
metrics. For most metrics, a gap was evident between the highest value for grade 0 and the 
lowest value for grade 3 esophagitis. 
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Figure 3.6: (a) Histogram showing the distribution of planning to week 1 Jacobian values for 
one patient, without anatomic corrections. Red line represents a normal fit. (b) Histogram 
showing the distribution of planning to week 1 Jacobian values for one patient, with all 
anatomic corrections applied. Red line represents a normal fit. (c) Boxplot of the planning to 
week 1 Jacobian full width half maximum (FWHM) values without and with anatomic 
corrections. (d) Boxplot of fraction of maximum expansion (MaxExp1) minus the fraction of 
maximum esophagitis grade, with a dotted line at zero. 
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Figure 3.7: (a-c) Boxplots of the esophageal expansion metrics grouped according to 
esophagitis grade (yellow is grade 0, white is grade 2, and gray is grade 3). The box edges 
represent the 75% (top edge) and 25% (bottom edge) quartile values, the middle line 
represents the median value, the whiskers represent the range of values, and the circles 
represent outliers. (d) Plot of the NTCP function for grade 2 (blue), and grade 3 (red) 
complication thresholds with individual patient result above (1.0) and below (0.0) the given 
threshold (blue +, grade 2; red o, grade 3). Expansion metrics are defined in the Methods and 
Materials section. 
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Table 3.1 summarizes the statistical relationships between expansion metrics and 
esophagitis grade. All expansion metrics were very highly significantly (p < 0.001) associated 
with esophagitis grade2 and 3 according to logistic regression. Spearman rank analysis showed 
most metrics to have correlation coefficients in the range of 0.50-0.67. While area under the 
curve (AUC) values from ROC analysis indicated metric performance varied slightly around the 
binary cutoff for grade 2 or grade 3, all MaxExp-based, PerExp95, LenExp30%, and LenExp40% 
metrics performed strong with AUC>0.88 for both esophagitis endpoints, indicating these 
metrics’ ability to classify esophagitis (Table 3.1).  
 
Table 3.1: Logistic regression analysis of the relationship between expansion metrics and 
esophagitis grade (n = 85).  
Expansion 
metric* 
Grade 2  Grade 3  
p AUC† 
Spearman 
rank 
50% 
Complication 
Value p AUC† 
Spearman 
rank 
50% 
Complication 
Value 
MeanExp 5.39E-08 0.855 0.553 1.191 3.87E-07 0.880 0.515 1.511 
MaxExp1‡ 1.51E-11 0.928 0.668 1.445 2.70E-07 0.899 0.540 2.123 
MaxExp3 1.72E-11 0.921 0.657 1.208 2.70E-07 0.893 0.532 1.880 
MaxExp5 2.44E-11 0.915 0.648 1.139 2.70E-07 0.899 0.540 2.145 
MaxExp7 5.98E-11 0.910 0.639 1.371 2.70E-07 0.900 0.542 2.039 
LenExp20% 2.08E-08 0.866 0.572 26.911 4.85E-06 0.860 0.488 127.848 
LenExp30% 5.98E-11 0.909 0.642 12.625 3.87E-07 0.901 0.546 98.625 
LenExp40% 4.10E-10 0.900 0.639 2.536 6.41E-07 0.899 0.553 80.554 
LenExp50% 1.26E-09 0.851 0.579 0.708 6.41E-07 0.894 0.564 64.979 
LenExp60% 1.56E-07 0.762 0.487 0.393 3.87E-07 0.889 0.606 49.769 
LenExp70% 8.41E-07 0.738 0.448 0.500 5.21E-06 0.831 0.530 40.571 
LenExp80% 1.93E-05 0.689 0.382 0.000 5.38E-05 0.784 0.492 31.333 
LenExp90% 1.48E-03 0.588 0.170 0.000 5.41E-05 0.783 0.475 23.571 
PerExp60 6.72E-07 0.815 0.491 1.133 1.29E-06 0.834 0.453 1.456 
PerExp70 4.66E-08 0.842 0.533 1.112 2.88E-07 0.894 0.534 1.764 
PerExp80 6.53E-09 0.864 0.568 1.083 2.70E-07 0.907 0.551 1.774 
PerExp90 4.10E-10 0.885 0.601 1.246 2.70E-07 0.902 0.545 1.910 
PerExp95 1.32E-10 0.902 0.627 1.252 2.70E-07 0.908 0.552 1.915 
*Expansion metrics as defined in section 3.1.4. 
†Area under the curve.  
‡Italic text indicates highest performing metrics for both grade 2 and grade 3 esophagitis endpoints.  
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The timing of maximum expansion and esophagitis grade showed a strong temporal 
correlation, as both esophagitis endpoints occurred on average around the same treatment 
fraction as the maximum expansion (Figure 3.7d). In addition, 8 patients had breaks in 
treatment due to esophagitis symptoms, with an average reduction of 14.3% in maximum 
expansion. 
 
3.2.3 Expansion & Breath Hold CT 
Similar to the 4DCT study cohort the anatomical correction methodology reduced the 
variance of Jacobian values. The mean FWHM for all 9 patients with weekly BHCT imaging was 
reduced from 0.27 (±0.38) to 0.23 (±0.55) after anatomical correction, yielding a 17.69% (±4.84) 
absolute percent difference. 
The comparative analysis of expansion calculated from BHCTs and 4DCTs for a single 
treatment week for 5 patients using the absolute difference between the expansion metric 
values is shown at the top of Table 3.2. For these five patients, the amount of expansion is 
consistent between both CT types for the given patient. The metrics values of the treatment 
week with largest expansion are consistent with the 4DCT cohort of the same esophagitis 
grade, as shown in the bottom of Table 3.2.   
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Table 3.2: Comparison of the absolute difference in expansion metric values calculated from 
either BHCT or 4DCT for 5 patients in relative units (top), and the expansion metrics values 
grouped according to maximum treatment esophagitis grade for 9 patients with weekly BHCT. 
The values in parentheses in the lower portion of the table represent the range of expansion 
metric values observed.    
 MaxExp1 MaxExp3 MaxExp5 LenExp30% LenExp40% PerExp98 
Mean Abs 
Difference 
0.098 0.104 0.102 15.5 11.0 0.09 
Max Abs 
Difference 
0.160 0.160 0.150 70.0 55.0 0.14 
Min Abs 
Difference 
0.061 0.061 0.040 0.0 0.0 0.07 
       
Grade MaxExp1 MaxExp3 MaxExp5 LenExp30% LenExp40% PerExp98 
G0 (N=4) 
1.17  
(1.13-1.27) 
1.15  
(1.10-1.24) 
1.12  
(1.05-1.21) 
0.00  
(0.00-0.00) 
0.00  
(0.00-0.00) 
1.07  
(0.94-1.17) 
G2 (N=2) 
1.55  
(1.43-1.67) 
1.51  
(1.36-1.65) 
1.49  
(1.35-1.62) 
56.25  
(27.50-85.00) 
28.75  
(2.50-55.00) 
1.44  
(1.35-1.52) 
G3 (N=2) 
1.98  
(1.93-2.03) 
1.95  
(1.89-2.01) 
1.91  
(1.83-1.98) 
121.25 
(85.00-157.50) 
98.75  
(77.50-125.00) 
1.77  
(1.71-1.83) 
 
 
 
3.3 Chapter Discussion 
To the best of our knowledge, this study was the first to propose an alternative measure 
of radiation esophagitis using objective, imaging biomarkers. In addition, we developed a 
method to reduce uncertainty in Jacobian calculations caused by esophageal anatomic 
variability. This study’s findings can be summarized as: first, the localized esophageal volume 
change, from planning to any weekly-treatment time point, can be calculated using the 
Jacobian; second, this correction methodology improves Jacobian calculation accuracy; third, 
the expansion metrics examined were significantly correlated to radiation esophagitis, with 
maximum esophagitis occurring near week of maximum expansion.  
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 Although transient effects can lead to erroneous Jacobian calculations, we found our 
correction methodology reduced these uncertainties. Using our correction methodology, we 
were able to reduce uncertainty by 10.0%, with air content producing the most error. Air in the 
esophagus is common, making censoring patients or sections of the esophagus with air not 
feasible.56 By utilizing the air content correction, we can obtain a more accurate Jacobian 
calculation in air-containing esophageal regions.  
We quantified esophageal expansion to measure esophagitis severity in a novel way. 
Previous studies observed expansion of the esophageal wall in many forms of esophagitis, 
including radiation esophagitis.12,51 However, these studies were presented as clinical 
observations, not thorough radiation-response analyses. In addition, these studies did not 
assess esophagitis severity. Previously, the relationship between esophagitis grade and the ratio 
of esophageal cross-sectional areas of weekly to planning CT images during treatment were 
studied and found that this ratio increased with grade, and these increases occurred in regions 
receiving the highest radiation doses.41 On the basis of this work, we improved our analysis by 
using a 3-dimensional measure of expansion. We developed localized measures of expansion 
and identified the highest correlated metrics to esophagitis grade. Furthermore, the timing 
relationship of maximum expansion and esophagitis grade was investigated. In addition, we 
corrected for anatomic variation to reduce the associated uncertainties. 
 Of the various esophageal expansion metrics we tested, most performed well and were 
highly correlated to esophagitis grade, as shown in Table 3.1. The highest performing metrics 
were maximum axial expansion (MaxExp1) and esophageal length ≥30% axial expansion 
(LenExp30%). The maximum axial expansion metrics seem intuitive as measures of high-grade 
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esophagitis, if the functional subunit of the esophagus is considered a cross-sectional segment, 
and the organ is serial. In addition, MaxExp1 and LenExp30% were combined into a multivariate 
logistic model for both endpoints and computed AUC.  An improvement in classification was 
observed for the grade 3 esophagitis endpoint, with AUC of 0.93 for grade 2 and AUC of 0.91 
for grade 3.  
 The timing of maximum expansion is correlated to esophagitis grade. On average, 
patients with maximum grade 2 esophagitis had maximum expansion occur at the same 
treatment fraction (Figure 3.7d). In addition, 15 of the 16 grade 3 max patients had expansion 
occur before grade 3 esophagitis. Whether expansion precedes grade 3 symptoms is not 
currently discernible as expansion and esophagitis scores are quantified weekly. The 
relationship with grade 2 esophagitis had more variance, but both this could be a product of 
subjectivity within grade 2 assessment. 
 The breath hold patient cohort of this study reflected the results of the 4DCT cohort. 
The anatomical corrections had a similar reduction in uncertainty. The extent of expansion 
metrics for patient esophagitis grade was consistent with observed values in the 4DCT cohort. 
The analysis of weekly 4DCT expansion metrics to those quantified on BHCT were consistent for 
most of the patients when weekly treatment CT time and patient grade were considered. Two 
of the five patients, however had discrepancies in expansion metric values.  
Our study had some limitations. First, a local error in deformable registration may cause 
miscalculation of the Jacobian. We reduced the potential impact of this miscalculation by 
implementing our correction methodology. In addition, there is no direct method to validate 
anatomic uncertainty late in treatment, and we assumed that the plan-to-week 1 variance is 
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representative of variance later in treatment. Nevertheless, patients with grade 0 esophagitis 
did not show any appreciable radiation-response, and even in extreme cases these patients 
exhibited little esophageal expansion. For every patient, expansion is a localized effect, with the 
expanding region only existing within the irradiated esophagus. Although dose-response may 
be considered a paradigm of radiation therapy, the goal of the current work was to show that 
esophageal expansion can quantify esophagitis, and dose was not a focus in our study. How 
dose induces esophageal expansion will be presented soon in a future study. We also did not 
conduct pre-treatment esophageal contrast studies, which allows for identification of pre-
existing thickening of the esophageal wall. In addition, chemotherapy does increase occurrence 
of high-grade esophagitis. How chemotherapy contributes to expansion is not thoroughly 
investigated. However, every patient in this study had the same course on concurrent 
chemotherapy, and no appreciable expansion was observed outside the irradiated esophagus. 
Due to small sample size, the results from the analysis of expansion calculated from BHCT only 
shows feasibility and needs to be verified with a larger data set. 
Quantifying esophagitis with expansion is an attractive method of quantifying 
esophagitis severity. The continuous nature of the expansion metrics may allow esophagitis 
severity to be described in mathematical rather than qualitative terms. The spatial localization 
of expansion allows geometric dose-response information, allowing for a deeper understanding 
of radiation injury in the esophagus, which was previously unavailable. Because esophagitis is 
an endpoint in most thoracic radiation therapy trials, expansion may potentially provide an 
objective measure for comparison of treatment modalities, as well as in-vivo measures of the 
effectiveness of radioprotectors.  
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This provides new options for toxicity prediction modeling. The binary endpoint of 
logistic regression can be chosen with flexibility. As shown in Figure 3.7, most expansion metrics 
had a gap between the minimal metric value for grade 3 esophagitis and the maximal metric 
value for grade 0. This gap as well as the expansion values of 50% probability of complication 
(Table 3.1) represents candidates for dichotomy. NTCP modeling is common practice to predict 
radiation esophagitis at treatment planning.2,3,5,57,58 In previous studies, variation in outcome 
reporting and differing grading scales presented challenges for obtaining effective NTCP 
models.2,21,24 Review studies by Werner-Wasik et al and Rose et al showed that although many 
NTCP-based studies have been performed with collectively thousands of patients, no common 
model can predict esophagitis with high accuracy in external data sets.2,3 The continuous 
nature of expansion metrics may  improve prediction model performance In addition, modeling 
techniques other than logistic regression may be studied. 
In conclusion, esophageal expansion is an imaging biomarker of radiation-response that 
is a suitable surrogate for toxicity. The highest performing expansion metrics were maximum 
axial esophageal expansion and axial length with at least 30% expansion. Expansion metrics 
may be useful to quantify response associated with new treatment techniques and clinical trials. 
The uncertainty in esophageal Jacobian calculations can be reduced by using anatomic 
correction methods. Use of breath-hold CT to calculate esophageal expansion is feasible. Breath 
hold CT would require multiple serial acquisitions to derive the anatomical variability correction 
factors, but these may be less impactful on the Jacobian calculation. However, more studies 
would be required using breath hold CT. 
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Chapter 4 
 
Prediction Modelling of Toxicity Using Esophageal Expansion 
 
 
In the previous chapter, the viability of using the esophageal expansion as a radiation-
response biomarker to quantify toxicity was shown. A natural application of a toxicity surrogate 
metric is its performance in toxicity prediction modelling. The work in this chapter investigates 
the use of esophageal expansion as an endpoint in the toxicity prediction modelling process 
with the goal of increasing model predictive performance. To accomplish this, toxicity 
prediction models were constructed with esophageal expansion endpoints and were then 
compared to toxicity prediction models constructed with traditional grade-based endpoints for 
severe radiation esophagitis. Multiple methods of toxicity prediction model construction were 
implemented within a cross-validation procedure. 
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4.1 Methods and Materials 
4.1.1 Patient Population 
The patients utilized for analysis in this chapter comprise of the same 85 patients from 
the IMRT arm of the prospective clinical trial at University of Texas-MD Anderson Cancer Center 
that had weekly 4DCT imaging, which were described in chapter 3. Patients had weekly 4DCT 
imaging which allows for the computation of esophageal expansion at each week during 
treatment. Esophagitis was graded according to Common Terminology Criteria for Adverse 
Events version (CTCAE) 3.0.19 The distribution of maximum esophagitis grades during treatment 
was: 24 were grade 0, 45 were grade 2, and 16 were grade 3. Out of a pool of 88 patients with 
weekly 4DCT and IMRT treatment from this clinical trial, the same 3 patients excluded in 
chapter 3’s analysis were excluded in this work due to poor image quality. The work in this 
chapter was approved by the University of Texas-MD Anderson Cancer Center Institutional 
Review Board and was HIPAA compliant. 
As previously described in chapter 3, 4DCT scans were acquired on CT scanners 
operated at 120 kV. Voxel dimensions were 0.98x0.98x2.50 mm in the right-left direction, 
anterior-posterior, and superior-inferior direction, respectively, with a 512×512 pixel area. 
Patient treatment planning and segmentation was conducted using the Pinnacle treatment 
planning system (Phillips Healthcare), with esophageal contours segmented from the cricoid 
cartilage to the gastroesophageal junction, in the axial plane, with Pinnacle version 9.8.  
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4.1.2 Logistic Regression  
Since NTCP models use dichotomization for outcome quantification, with 1 representing 
complication occurrence, and 0 representing no complication occurrence, logistic regression 
with is a natural choice for statistical analysis. We define the logistic model as: 
 
 𝑁𝑇𝐶𝑃 =  
1
1+𝑒−(𝛼0+𝛼1 ∗𝑥1+…+𝛼𝑛 ∗𝑥𝑛)
      (4.1) 
 
for a model with n predictor variables, denoted 𝑥𝑖 , where 𝛼𝑖 are the regression coefficients. 
 
4.1.3 Forward, Stepwise Model Selection 
While there are many ways to select model predictor variables, one of the most 
traditional is the forward, stepwise selection method.6,33,34 Starting with a null model, each 
predictor variable is added and the ratio likelihood test is used to identify which individual 
predictor performs best for the given model order. In addition, Bayesian information criterion 
(BIC) is calculated for each model order; when BIC is minimized, this is selected as the optimal 
model order to prevent overfitting.  
 
4.1.4 Least Absolute Shrinkage and Selection Operator (LASSO) 
While stepwise selection is common for NTCP model creation, the LASSO has been 
shown to have improved prediction ability.64-66 The predictor variable selection methodology in 
LASSO identifies the subset of the regression coefficients, 𝛼𝑖 , equal to zero, using the penalty 
term, λ, by minimizing the following equation: 
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 ∑ (𝑌𝑖 −
1
1+𝑒−(𝛼0+𝛼1 ∗𝑥1+…+𝛼𝑛 ∗𝑥𝑛)
)2𝑛𝑖=1 +  λ ∑ |𝛼𝑖|
𝑛
𝑖=1      (4.2) 
 
for n number of predictors, where 𝑌𝑖 is the complication outcome. For a larger λ, less variables 
will be utilized in the model.62  
 
4.1.5 Random Forest Classification 
Random Forests classification is a wholly different modelling approach than stepwise or 
LASSO logistic regression, since there is no longer an attempt to fit a logit analytical function.62 
Random Forests is an ensemble decision tree approach with an implementation of bootstrap 
aggregation, or bagging, and a random draw of a set-sized subset of model predictors at each 
tree node.69 The result of this procedure is an ensemble of de-correlated trees that should 
increase generalizability of the model. In our implementation of Random Forests, the number of 
randomly drawn predictors from the training data was 7 for each node (the square root of the 
number of predictors). The number of trees in the ensemble was 300, to allow for sufficient 
stabilization, and the minimum leaf observation size was 1 for all trees. 
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4.1.6 Objective Esophagitis Endpoints 
As shown in chapter 3, esophageal expansion calculated from the radiation therapy 
treatment planning CT to weekly treatment 4DCTs is a surrogate quantification of radiation 
toxicity in the esophagus. In addition, the analysis in chapter 3 showed that the maximum axial 
expansion of one slice (MaxExp1), and the axial esophageal length with at least 30% expansion 
(LenExp30%), were the highest performing endpoints for quantifying grade 3 esophagitis. In 
this chapter’s analysis, these two expansion biomarkers are examined separately as endpoint in 
the toxicity prediction modelling process. The scientific question of this analysis is: can these 
surrogate endpoints produce better performing prediction models, in terms of prediction 
performance, than using an esophagitis grade input. 
 While the objective expansion metrics are continuous, to get a direct comparison of 
NTCP performance with traditional grade-based endpoint models, the patients had their 
MaxExp1 and LenExp30% biomarker values dichotomized according to a threshold value for the 
given metric. This threshold value was chosen to be the intersection value of the grade 0 and 
grade 3 distributions for the particular metric: 50% for MaxExp1, and 45mm for LenExp30%. An 
example for the determination of this intersection metric value is given by the dotted red line 
for MaxExp1 in Figure 4.1.  
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Figure 4.1: Determination of the threshold value for endpoint dichotomization of patients as 
either having the complication or not having the complication for the MaxExp1 expansion 
biomarker. The dotted red line represents the intersection of grade 0 and grade 3 MaxExp1 
metric values and is the threshold metric value (MaxExp1 of 1.5 in relative units and 50% in 
units of percent expansion).  
 
 
4.1.7 NTCP Model Assessment: Repeated Holdout Cross-Validation 
For all model construction methods, repeated holdout cross-validation, also known as 
Monte Carlo cross-validation was utilized to randomly partition patient data in the model 
construction process.62,70 The patient data are comprised of the clinical factors and DVH dose 
metrics that are used as model predictors, as well as the individual patients’ endpoints, 
specifically esophagitis grade, MaxExp1, and LenExp30% objective values. The toxicity predictor 
variables were clinical factors consisting of: age, gender, tumor prescription dose, tumor 
location, tumor stage, tumor histology, gross tumor volume, nodal involvement, if the patient 
had induction chemotherapy, and smoking status (former smoker, current smoker, never 
smoked).  Esophagus DVH dose metrics included: maximum (Dmax) and mean esophagus dose 
(MED), absolute volume of dose from 10Gy to 70Gy in 5Gy increments, esophageal length 
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receiving ≥ 10Gy to 50Gy in 10Gy increments for both 25% and 100% circumference coverages 
of the esophagus.  
Approximately 75% of the data (64 patients) are partitioned into the training data set for 
model construction and fit assessment. The remaining 25% of the original patient data set is 
held out for assessing model prediction performance. This process starts by randomly splitting 
the dataset into the aforementioned training and test data sets. A toxicity prediction model is 
constructed on the training data set for all three model types simultaneously (stepwise, LASSO, 
and Random Forests). There is a unique step in the LASSO model methodology, whereby the 
optimal penalization parameter, λ, is calculated by 5-fold cross-validation with deviance as the 
optimization measure on the training data set. 
The fit performance of the model is assessed by predicting the known outcomes of 
patients in the training set by using each patient’s respective predictor variables and 
corresponding outcome, in the derived model. The model order of the fitted models, as well as 
the predictors present in the models are all cataloged. Model predictive performance is then 
assessed by applying the developed model to each patient in the test data set. In both the fit 
and predictive model assessments, area under the curve (AUC) from receiver operating 
characteristics analysis is used to quantify performance. This process is repeated for 100 
iterations to account the randomness of partitioning the full data into training and test sets. 
This model construction methodology is performed for all 3 endpoint types (Grade, MaxExp1, 
and LenExp30%), separately. The distribution of AUCPrediction values are tested for significant 
differences between all model methods and endpoint types with a paired T-test (p<0.05 for 
significance).  
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Figure 4.2 illustrates the iterative process of the model construction methodology. The 
model order and predictor variables present in the model are recorded. Since Random Forests 
is an ensemble approach, recording model order and predictor variable occurrence in the 
model is not informative. Therefore, predictor importance is quantified with the out-of-bag 
permutation error, which is the average increase in prediction error is as variables are permuted 
on observations that are out-of-bag for the entire ensemble. 
 
 
Figure 4.2: Schematic of the model construction and assessment process. This represents a 
single iteration of 1000 total iterations of the repeated cross-validation process. For each 
iteration, a model is trained on the training set from 75% of the full patient data, based on a 
random partition. The trained model is assessed on the test set consisting of the remaining 25% 
of full patient data, to simulate external validation and prediction performance. This process is 
executed 1000 times with a different random partition of test and training data.  
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4.1.8 Computational Implementation 
All predictor variables were standardized by subtracting the mean variable value of all 
patients from each individual patient value, and then dividing the result by the standard 
deviation.70 All computations were conducted in MATLAB (Mathworks, Natick, MA) version 8.2. 
Forward stepwise logistic regression and Random Forests classification models were 
constructed with MATLAB’s machine learning and statistics toolbox. LASSO models were 
constructed using the open source glmnet package implemented in MATLAB.72 It should be 
noted that for each model construction method using different endpoints, the same random 
number seed is initialized before any computations.  
 
 
4.2 Results 
4.2.1 Patient Population 
Clinical factors, Radiotherapy Prescription dose, and maximal esophagitis grade during 
treatment for the 85 study patients are summarized Table 4.1. The median week of maximal 
esophageal expansion was week 6 (range, 4-8).  A summary of DVH dose metrics for this 
population is shown in Table 4.2. 
 
 
 
 
 
47 
 
Table 4.1: Demographic characteristics of the 85 study patients. 
    Characteristic Datum 
Median age (range) 
 
All 65 years (43-85 years) 
Male 65 years (47-80 years) 
Female 66 years (43-85 years) 
Sex 
 
No. of Males 45 
No. of Females 40 
Histologic findings 
 
Squamous cell    
    carcinoma 
29 
Adenocarcinoma 50 
Large cell  
    carcinoma 
3 
Other 3 
Smoking history 
 
Current smoker 18 
Former smoker 58 
Never smoked 9 
Stage 
 
IIa 3 
IIb 3 
IIIa 39 
IIIb 36 
IV 4 
Treatment dose, Gy 
 
74 53 
66 28 
60 4 
Max Esophagitis Grade  
Grade 0 24 
Grade 2 45 
Grade 3 16 
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Table 4.2: Summary statistics for dose-volume histogram metrics for the 85 study patients, 
including mean, standard deviation, maximum, and minimum metric values. The units are Gy for 
MED and Dmax, cm3 for V10-V70, and esophgeal length in cm for LE metrics. 
DVH Metrics Mean S.D. Max Min 
MED 71.53 11.11 83.06 20.64 
Dmax 30.02 10.50 53.17 3.99 
V10 20.11 8.37 51.72 3.24 
V15 18.66 8.43 49.81 0.25 
V20 17.31 8.39 47.86 0.01 
V25 16.04 8.23 44.57 0.00 
V30 14.97 8.00 43.71 0.00 
V35 13.92 7.67 42.67 0.00 
V40 12.85 7.41 41.19 0.00 
V45 11.73 7.10 38.57 0.00 
V50 10.47 6.74 35.06 0.00 
V55 9.09 6.14 30.24 0.00 
V60 7.10 5.02 21.21 0.00 
V65 4.61 3.98 18.86 0.00 
V70 2.46 3.39 16.09 0.00 
LE1025% 13.39 3.33 20.00 4.75 
LE2025% 12.05 3.36 19.00 2.75 
LE3025% 10.52 3.68 18.50 0.00 
LE4025% 9.23 3.85 18.00 0.00 
LE5025% 8.10 3.72 17.50 0.00 
LE6025% 6.23 3.13 14.75 0.00 
LE10100% 12.06 3.73 19.00 0.50 
LE20100% 9.48 3.86 18.00 0.50 
LE30100% 7.63 3.68 17.50 0.25 
LE40100% 6.18 3.15 15.00 0.25 
LE50100% 4.93 2.68 12.75 0.25 
LE60100% 3.43 1.84 7.00 0.25 
Abbreviations:  MED = mean esophagus dose; Dmax = maximum esophagus dose; V10 = 
volume of esophagus receiving at least 10 Gy; LE1025% = esophageal length with at least 10 Gy 
to at least 25% of the cross-sectional area to axial slice of the esophagus; LE10100% = 
esophageal length with at least 10 Gy to at least 100% of the cross-sectional area to axial slice 
of the esophagus. 
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4.2.2 Model Construction 
A total of 49 predictor variables were inputs to the toxicity prediction model 
construction process, as summarized in Table 4.3. For model construction with the grade 3 
endpoint, the most common model order was 7 terms for the forward stepwise, and 9 for the 
LASSO implementation. Models using the objective MaxExp1 ≥ 50% endpoint had most 
common model orders of 6 for stepwise, and 11 for LASSO. LenExp30% ≥ 45mm endpoint-
based models had an average model order of 6 for stepwise and 7 for LASSO. 
The most common predictor variables in all models are recorded in Table 4.3. For grade-
based endpoint models, clinical factors were the highest recurring predictor type with LE60100% 
being the sole DVH metric in the top-five recurring model predictors. This was a similar result in 
the grade-based endpoint LASSO models, where LE60100% and V70 were the second and fifth 
most recurring predictors in the fitted models, respectively. This was not the case for the 
Random Forests grade endpoint models, where no clinical factors were in the top-five of most 
recurring model predictors. For both LenExp30% and MaxExp1 objective endpoint-based 
models, dosimetric predictors were the most recurring, specifically LE40100% which was the first 
or second highest recurring predictor in all model types. Mean esophageal dose was also 
present in all model types. 
The fit performance of each model type for each endpoint is also displayed in Table 4.3. 
All scenarios except one had average AUCFit >0.90, showing strong calibration of each model. 
Stepwise model type showed the highest average AUCFit.   
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Table 4.3: Results of toxicity prediction model construction for 85 patients using stepwise 
logistic regression, LASSO logistic regression, and Random Forest classification. Each model 
type was constructed with complication endpoints of: esophagitis ≥ grade 3, maximum axial 
expansion of one slice (MaxExp1) ≥ 50%, and esophageal length with expansion of at least 30% 
(LenExp30%) ≥ 45mm, separately. The area under the curve from model fitting on training data 
and model prediction on test data is denoted AUCFit and AUCPrediction, respectively. Highest 
recurring predictors are listed in order of most to least recurring, for all model predictors 
occurring in at least 500 out of 1000 iterations of the cross-validation procedure. 
Model 
Type 
Endpoint 
AUCFit 
(S.D.) 
AUCPrediction 
(S.D.) 
Highest Recurring Predictors 
     
Stepwise 
Esophagitis≥ 
Grade 3 
0.99 (±0.01) 0.58 (±0.15) 
Age, Tumor Location, Induction 
Chemo, LE60100%, Smoking Status 
LASSO 0.91 (±0.10) 0.64 (±0.12) 
Tumor Location, LE60100%, Age, 
Smoking Status, V70 
Random 
Forest 
0.97 (±0.05) 0.55 (±0.07) V55, LE50100%, LE40100%, MED, V40 
     
Stepwise 
MaxExp1 ≥ 
50% 
0.96 (±0.02) 0.66 (±0.18) LE40100%, V50, Stage, MED, Dmax 
LASSO 0.90 (±0.06) 0.75 (±0.10) LE40100%, V70, Stage, MED, Dmax 
Random 
Forest 
0.99 (±0.02) 0.76 (±0.10) 
LE40100%, LE50100%, LE30100%, V70, 
MED 
     
Stepwise 
LenExp30% 
≥ 45mm 
0.96 (±0.02) 0.69 (±0.13) 
Stage, LE40100%, MED, Tumor 
Location, Dmax 
LASSO 0.84 (±0.08) 0.73 (±0.10) 
LE40100%, MED, Stage, LE3025%, 
LE50100% 
Random 
Forest 
0.99 (±0.03) 0.73 (±0.10) 
LE50100%, LE40100%, V55, MED, 
LE30100% 
Abbreviations:  MED = mean esophagus dose; Dmax = maximum esophagus dose; V10 = 
volume of esophagus receiving at least 10 Gy; LE1025% = esophageal length with at least 10 Gy 
to at least 25% of the cross-sectional area to axial slice of the esophagus; LE10100% = 
esophageal length with at least 10 Gy to at least 100% of the cross-sectional area to axial slice 
of the esophagus. 
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4.2.3 Model Prediction 
The prediction performance of the different model types with the three endpoints is 
quantified with AUCPrediction and is displayed in Table 4.3. The mean AUCPrediction value for 
models using the grade 3 endpoint is 0.58, 0.64, and 0.55 for the stepwise, LASSO, and Random 
Forests, respectively.  The mean AUCPrediction value for models using the objective 
MaxExp1≥50% endpoint is: 0.66, 0.75 and 0.76 for the stepwise regression, LASSO, and Random 
Forests, respectively. The mean AUCPrediction value for models using the objective 
LenExp30%≥45mm endpoint is: 0.69, 0.73 and 0.73 for the stepwise regression, LASSO, and 
Random Forests, respectively. Standard deviation of AUCPrediction values are generally lower for 
LASSO and Random Forests models using either objective endpoint than either the grade-
based endpoint models, or the stepwise model type. A boxplot of AUCPrediction values from all 
iterations of the model construction and assessment methodology is shown in Figure 4.3. The 
AUCPrediction values for the Random Forests and LASSO methods using either objective endpoint 
were significantly higher than AUCPrediction values from all methods using the grade endpoint. 
Additionally, AUCPrediction values from LASSO and Random Forests methods were significantly 
higher than the stepwise method when using either objective endpoint. 
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Figure 4.3: Boxplot of AUC values of model prediction using holdout test data for all 100 
iterations of the repeated cross-validation procedure. Endpoints were grade 3 esophagitis (light 
blue), and the objective endpoint MaxExp1≥50% (medium blue), and LenExp30%≥45mm (dark 
blue). The first group of three individual boxplots are models constructed with stepwise logistic 
regression, the second grouping is LASSO, and the final group is Random Forests. The 
individual boxes represent the respective quartiles, with the solid black line in the box 
representing the median AUC value, as well as the solid black circle representing the mean AUC 
value. Outliers are denoted with gray ‘+’ symbols. 
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4.3 Chapter Discussion 
The work in this chapter represents a novel investigation of the use of objective 
measures of esophageal toxicity in the prediction modelling process. Several comprehensive 
review publications in the literature identified the need for objective imaging biomarkers with 
application in toxicity prediction modelling.67,68 The work in this chapter specifically addresses 
this issue. Prediction models were constructed with two different logistic regression methods 
and a Random Forests classifier, all using the traditional grade 3 endpoint, and directly 
comparing the modelling process with objective esophagitis measures as endpoints in the form 
of the MaxExp1 ≥ 50% and LenExp30% ≥ 45mm. 
 There was consistency in predictor variables chosen for model selection, regardless of 
model construction method or model endpoint. Mean esophageal dose (MED) and length of 
esophagus receiving at least 40Gy to 100% of the esophageal circumference (LE40100%), were 
consistently selected as variables for the prediction models. This is consistent with previous 
esophagitis toxicity studies.2,3 Mean esophageal dose and length of esophagus receiving at 
least 40Gy to the entire esophageal circumference were commonly selected in all objective 
endpoint-based scenarios, which showed higher prediction performance then the grade-based 
endpoint models. Interestingly, irradiated length of the esophagus was shown to be correlated 
to toxicity and may infer an ability to partially spare the esophagus. A strong fit was obtained 
on the training data for all model types and endpoints, as shown in Table 4.3. 
It is important to note that true prediction ability must be tested on data not used in the 
NTCP model process. As an example, the stepwise method with the grade endpoint has a mean 
AUCFit of 0.99. Without cross-validation one may conclude this is a robust prediction modelling 
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method. However, the mean AUCPrediction value is only 0.58 for this model, indicating severe 
overfitting. 
The prediction ability, as quantified by AUC on the test sets of data, is illustrated in 
figure 2 for all 9 modelling scenarios (3 model construction methods, 3 endpoints). From this 
figure, a general trend of increase AUCPrediction with a smaller variance can be seen with Random 
Forests and LASSO models using objective endpoints compared to the grade endpoint. In 
addition, the prediction performance is increased by using LASSO or Random Forests compared 
to stepwise logistic regression, with the exception of the Random Forests method using the 
grade 3 endpoint. 
Comparing the AUCFit to AUCPrediction for respective model method and endpoint type 
shows a smaller difference between model training and testing performance for the LASSO and 
Random Forests methods using the objective endpoints, when compared to the stepwise 
method and grade endpoints. This indicates the LASSO and Random Forests models, as well as 
the objective biomarker endpoints are more generalizable model construction methods than 
stepwise regression or the grade 3 endpoint. The observed superiority of LASSO to stepwise 
regression for NTCP modelling is consistent with previous studies.64-66   
There were several limitations with this analysis. Generally, a larger sample size is 
desired in prediction modelling, and the 85 patient sample in this study is on the lower end of 
common experience.2,3 However, the need for weekly 4DCT acquisition during treatment to 
calculate esophageal expansion limits the amount of patients currently available for analysis. 
Another limitation was the inability of our study to report a single ‘superior’ model. Typically, 
NTCP modelling studies report a full logistic regression equation with predictor variables and 
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coefficients for comparison with existing and future models. However, our goal was not to find 
a single ‘superior’ model, but to analyze the performance of objective esophagitis endpoints in 
the NTCP modelling process, with comparison to traditional grade based endpoints. In addition, 
we wanted to compare the performance of a common predictor selection method (stepwise 
regression) with two promising techniques, LASSO and Random Forests.  
The results from this chapter show the utility of esophageal expansion as objective 
biomarker endpoints for toxicity prediction modelling. In addition, we have shown the superior 
predictive performance of LASSO and Random Forests compared to stepwise models in the 
toxicity prediction modelling process for esophagitis. Further investigations into using objective 
esophagitis endpoints for more robust prediction models may now be explored. 
 In conclusion, objective, localized measures of esophageal toxicity in the form the 
expansion biomarkers maximum axial expansion of one slice of the esophagus (MaxExp1) and 
esophageal length with at least 30% expansion (LenExp30%), with respective complication 
thresholds of 50% and 45mm, have higher predictive performance than CTCAE grade for 
prediction models of severe esophagitis. All model types showed irradiated length of the 
esophagus as a common predictor of toxicity. LASSO and Random Forests model types 
outperform forward, stepwise model selection for predicting severe esophagitis. 
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Chapter 5 
 
Normalized Uptake from 18Fluorodeoxyglucose Positron Emission 
Tomography as a Measure of Esophageal Radiation Injury 
 
  
This chapter investigates normalized FDG uptake, as quantified from mid-treatment 
FDG-PET/CT imaging, as a radiation-response and toxicity measure for esophageal radiation 
injury. Robust metrics of normalized FDG uptake are derived for classification of toxicity. A 
methodology to normalize FDG uptake as a radiation-response metrics is tested. These 
normalized FDG uptake metrics are then shown to be robust biomarkers of esophageal 
radiation-response and esophageal toxicity, by statistical analysis with physician scored 
radiation esophagitis grade. The highest performing normalized uptake metrics are then 
analyzed as predictors of esophagitis symptom development from patients who are 
asymptomatic at the time of the FDG-PET study. In addition, the relationship between FDG 
uptake and esophageal expansion was examined. This chapter comprises specific aim 2.  
 
A substantial portion of this chapter is based on the following publication:  
Niedzielski JS, Yang J, Liao Z, Gomez DR, Stingo F, Mohan R, Martel MK, Briere TM, Court LE. 
18F-fluorodeoxyglucose-positron emission tomography can quantify and predict esophageal 
injury during radiation therapy. Int J Radiat Oncol Biol and Phys 2016 96(3):670-678. 
 
doi: 10.1016/j.ijrobp.2016.07.012 
©Elsevier 
 
Written permission for reuse of these materials was obtained from Elsevier Publishing. 
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5.1 Methods and Materials 
5.1.1 Patient Population 
The patient population studied in this chapter was from the same pool of patients from 
a prospective clinical trial for treatment of NSCLC. We identified 79 patients for this 
retrospective analysis that had a single FDG-PET/CT scan acquired during treatment. As 
mentioned in previous chapters, all patients in this clinical trial were treated with concurrent 
chemotherapy (paclitaxel and carboplatin) and either intensity-modulated photon radiation 
therapy or passive-scatter proton radiation therapy, with a tumor prescription dose of 60-74 Gy 
in 2-Gy fractions over 6-8 weeks. Of these 79 patients for this FDG-based study, 67 patients 
were included that also had expansion calculated during treatment. Of these 67 patients, 36 
were included in the analyses from chapters 3 and 4. 
Esophagus contours were segmented in the axial plane from the cricoid cartilage to the 
gastroesophageal junction. Esophagitis was prospectively scored weekly throughout treatment 
using the Common Terminology Criteria for Adverse Events 4.0. The distribution of esophagitis 
grades was as follows: 43 grade 0, 30 grade 2, and 6 grade 3 at the time of the PET studies, and 
progressed to maximum esophagitis of 17 grade 0, 40 grade 2, and 22 grade 3, by treatment 
completion. For the 43 grade 0 patients at time of the PET study, 26 would progress to have 
esophagitis (23 grade 2, 3 grade 3).  
All PET/CT scans were acquired with a General Electric Discovery ST PET/CT scanner (GE 
Medical Systems, Waukesha, WI) with 3.9×3.9×3.3mm3 voxels. PET/CT studies were acquired in 
the treatment position with standard patient immobilization used for radiation therapy 
planning CT scans. All PET studies were attenuation-corrected with an accompanying CT scan. 
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PET scans were conducted at a median of 100.1 minutes (range, 58.1-159.2 minutes) after 
injection of a median of 377.0 MBq (range, 241.4-507.2 MBq) of FDG. The PET/CT scans were 
deformed using a B-splines image registration algorithm in the planning CT frame of reference 
and resampled into 0.98×0.98×2.50mm3 voxels using Velocity AI 3.0.1 (Velocity Medical 
Solutions, Atlanta, GA). The timing of the PET studies during treatment was not uniform. On 
average, the PET scan was acquired at fraction 23 (±2.4 standard deviation, 18-28 range).  
 
5.1.3 Normalized FDG Radiation-Response 
We developed in-house code for data extraction, uptake calculation, and analysis using 
MATLAB (Mathworks, Natick, MA). This software converted the planning CT esophagus 
segmentations into binary masks for identification of esophageal voxels in image space. Using 
spatial reference points from the corresponding digital imaging and communications in 
medicine (DICOM) header file, spatial positioning in Cartesian coordinate space of each voxel 
can be identified for both the FDG-PET and radiation dose arrays. From this information, the 
FDG-uptake and radiation dose for each voxel in the esophagus can be identified. FDG uptake 
was quantified as the standard uptake value (SUV) according to the bodyweight calculated SUV 
equation, with voxel SUVMean and SUVMax calculated.73,74 
To control intra-patient FDG uptake variability, uptake was normalized as a patient-
specific radiation-response quantification. For each patient, we calculated a normalization factor 
of the mean SUV value for esophageal voxels irradiated up to a X Gy low-dose threshold, for 
delivered dose at the time of the PET study, and then divided the remaining esophageal PET 
voxels above the low-dose threshold by this normalization factor.   
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The normalized SUV equation is: 
  𝑛𝑆𝑈𝑉(𝑥, 𝑦, 𝑧) = (
𝑆𝑈𝑉(𝑥,𝑦,𝑧)>𝑋 𝐺𝑦
𝑆𝑈𝑉𝑀𝑒𝑎𝑛<𝑋 𝐺𝑦
− 1) ∗ 100     (1) 
Where SUVMean < X Gy is the average FDG uptake in the low-dose region (less than X Gy) of the 
esophagus and uptake value. Normalization low-dose cutoff value was analyzed for threshold 
values of X = 1, 2, 5, 8, and 10-Gy. The multiple choices of the low-dose threshold were 
examined to test the sensitivity of the choice of the threshold value. The normalized SUV 
(nSUV) represents the percent uptake increase from the low-dose esophageal region due to the 
corresponding radiation dose. SUV(x,y,z)>X Gy is the given voxel FDG uptake.  
 Localized uptake metrics were derived by averaging nSUV at each axial segment of the 
esophagus in two ways: axial-averaged maximum nSUV for 1, 3, 5, and 7-slices (e.g., nSUVAxMax7 
for the 7-slice average) and axial length of esophagus with at least a given percentage of axial-
averaged nSUV response (e.g., nSUVLen40 for esophageal length with nSUV ≥ 40% axial-
averaged normalized response), with an nSUV increase ranging from 20% to 60% in 10% 
increments. Voxel nSUV mean (nSUVMean), maximum (nSUVMax), and percentile nSUV values 
from sixty-fifth to ninety-fifth percentile (e.g., nSUVPerc65 for the sixty-fifth percentile) were also 
calculated. Standard SUV values of SUVMax and SUVMean were also reported.  
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5.1.4 Esophagitis Timing and Progression  
The relationship between esophagitis grade (both maximum grade and grade at the 
time of the PET study) and normalized uptake was examined. The timing of esophagitis severity 
and progression to maximum grade was analyzed in terms of treatment fractions between the 
PET scan and the escalation of grade, and then compared with nSUV.  
The ability of mid-treatment nSUV to predict maximum esophagitis grade was also 
investigated for patients who were asymptomatic during the PET study. These patients were 
grouped as: grade 0 at the time of the PET study that remained grade 0 throughout treatment 
(G0-0), grade 0 that became grade 2 or 3 (G0-2/3), grade 2 that stayed grade 2 (G2-2), grade 2 
that became grade 3 (G2-3), and grade 3 that stayed grade 3 (G3-3). Progression for G2-3 
patients was not analyzed due to low sample size. No patients had esophagitis grade escalate 
after completion of radiation therapy. Prediction of symptom progression from asymptomatic 
patients during the PET study (n = 43) was created using LASSO logistic regression and nSUV 
metric values. Model construction is described in section 5.1.6.  
 
5.1.5 Normalized FDG Uptake & Esophageal Expansion  
 A natural question arises of how FDG uptake and esophageal expansion relate for a 
given patient. A total of 67 out of the 79 patients in this analysis had esophageal expansion 
quantified calculated from 4DCTs for the same week of FDG-PET acquisitions. This allowed the 
FDG uptake and expansion to be compared at the same time point during treatment for a given 
patient.  
 
61 
 
5.1.6 Statistical Considerations 
FDG uptake and dose metrics were compared with esophagitis grade, both at the time 
of the PET study and maximum treatment grade, for ≥ grade 2 esophagitis complication using 
univariate logistic regression and Spearman rank analysis. Model fit was assessed using area 
under the curve (AUC) from receiver operating characteristics (ROC) analysis. Reported Logistic 
regression p-values were calculated using the likelihood ratio chi-square test. Prediction of 
maximum esophagitis grade from mid-treatment nSUV was tested using the Mann-Whitney U 
test. All p-values were reported after applying the Benjamini-Hochberg false discovery 
procedure. A p-value of ≤0.05 was considered statistically significant.  
To test the relationship of nSUV and esophagitis grade in a multivariate analysis, least 
absolute shrinkage selection operator (LASSO) penalized logistic regression was utilized. LASSO 
has the ability to ignore redundant features and improve predictive ability when compared to 
stepwise logistic regression.62,64,65,66 Model features in the form of nSUV were used to predict 
≥ grade 2 esophagitis at time of PET study, and ≥ grade 2 maximum treatment grade. A 3-fold 
cross-validation procedure (folds of 1 training, 1 validation, and 1 test) was repeated for 100 
iterations, with AUC calculated from NTCP predictions (probability of ≥grade 2 esophagitis 
incidence) on the test fold for every iteration. The AUCMean and standard deviation of AUC 
values quantifies the robustness of the trained nSUV model to classify esophagitis on the test 
set. LASSO model parameters were derived from the validation set and the tested model was 
constructed from the training set.  
To investigate the added value of nSUV in classifying esophagitis, dosimetric features 
were examined as separate model features and then repeated with nSUV features to predict 
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≥grade 2 esophagitis in the model construction method previously described. Dosimetric 
features were quantified using dose-volume histogram (DVH) metrics in the form of esophagus 
volume receiving at least X dose (VX), length of esophagus irradiated to at least X dose with 
complete esophageal axial coverage (LEX), and mean (MED) and max (Dmax) esophageal dose. 
Dose metrics were also quantified and separately tested in model construction in the form of 
fractional DVH metrics, for each patient’s fraction at time of the PET study. 
The previously described model construction method was implemented with 
asymptomatic patients at time of the PET study (n=43), to predict symptom progression by 
completion of treatment (≥ grade 2). Model construction of nSUV-only, dose-only, and nSUV 
and dose features were conducted.  
 
5.2 Results 
5.2.1 Patient Characteristics 
Clinical factors of the 79 patients studied are summarized in Table 5.1. No clinical factors 
were associated with esophagitis grade, either maximum grade or grade during the PET study. 
Neither injected FDG dose nor PET scan times were correlated to nSUV metrics. In addition, the 
timing of the PET study was not associated with esophagitis or nSUV metrics’ value. 
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5.2.2 Normalization of FDG Uptake 
The normalization factor was calculated for threshold values of 1, 2, 5, 8, and 10 Gy for 
50 of the 79 patients studied. The 5Gy threshold was selected. The average percent difference 
between using 5Gy normalization factor versus other examined threshold values was 2.36% 
(±2.00% standard deviation), with four patients more than 6.00% (10.48% maximum). In 
addition, nSUV metrics were calculated for these 50 patients and the effect of different 
threshold values was analyzed. None of the metrics had an average difference of more than 
4.8% for an individual patient. Since effect of threshold choice was minimal, two patients had 
nSUV metrics calculated with different normalization factor thresholds (1Gy, 8Gy) to acquire an 
adequate amount of normalization voxels for analysis. The necessity of normalizing the SUV 
value can be illustrated by comparing Figure 5.2 (no normalization) to Figure 5.3a,b (with 
normalization). The stratification of esophagitis grade by SUV magnitude is stronger with 
normalization (Figure 5.3) than without (Figure 5.2). In addition, the meaning of the SUV metric 
is stronger and more appropriate for analyzing dose-response, as the metric has been 
normalized according to a patient’s radiation response characteristics. 
 
5.2.3 Normalized FDG Uptake and Esophagitis Severity 
Normalized uptake generally increased along with esophagitis severity. This was true of 
both esophagitis grade measured during the PET study, and treatment maximum. For each 
patient, increased normalized uptake was confined to the region of highest radiation dose 
along the length of the esophagus (Figure 5.1).  
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Table 5.1: Demographic characteristics of the 79 study patients. 
Characteristic Datum 
Median age (range) 
 
All 66 years (38-80 years) 
Male 65 years (51-79 years) 
Female 66 years (38-80 years) 
Sex 
 
No. of Males 46 
No. of Females 33 
Histologic findings 
 
Squamous cell carcinoma 31 
Adenocarcinoma 41 
Large cell carcinoma 3 
Other 4 
Smoking history 
 
Current smoker 27 
Former smoker 46 
Never smoked 6 
Stage 
 
IIa 3 
IIb 5 
IIIa 29 
IIIb 38 
IV 4 
Treatment dose, Gy 
 
74 46 
66 28 
60 5 
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Figure 5.1: Sagittal view of esophageal anatomy as measured by computed tomography (CT; 
left panels) with radiation dose and normalized uptake in the sagittal plane (right panels) for an 
asymptomatic patient (68 year old male), a,b, and a patient (73 year old male) with grade 3 
esophagitis at the time of the positron emission tomography (PET) study, c,d. The esophagus is 
outlined in blue on the CT scans, with radiation planning isodose lines of 20 Gy (light blue), 30 
Gy (orange), 40 Gy (red), 50 Gy (yellow), 60 Gy (purple), and 70 Gy (dark green) . The region of 
high esophageal dose and corresponding normalized standard uptake value (nSUV) is 
highlighted with the black arrows. 
 
66 
 
 
 
Figure 5.2: Esophagus FDG standard uptake values without normalization for voxel mean 
uptake (SUVMean) in (A) and voxel max uptake (SUVMax) in (B)  for patients with grade 0, 2, or 3 
maximum esophagitis grades,. Boxplot corners represent 25th and 75th percentiles and middle 
line the median value. Outliers are denoted as ‘+’. 
 
The ability of nSUV to stratify patients on the basis of esophagitis grade at the time of 
the PET study, as well as the maximum esophagitis grade, is shown for nSUVAxMax1 in Figure 
5.3a,b. A strong trend of increasing nSUV with increasing esophagitis severity is observed. 
Grouping patients’ esophagitis grade during the PET study and the maximum grade showed a 
trend of increasing normalized uptake with increasing esophagitis severity (Figure 5.3c). Figure 
5.3 shows the ability of nSUV to stratify esophagitis severity, as well as esophagitis progression, 
from the time of the FDG-PET study to treatment completion; for comparison, boxplots of the 
mean and maximum esophageal dose grouped according to esophagitis grade are presented in 
the supplemental materials. 
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Figure 5.3: Esophagus FDG axial-averaged maximum normalized standard uptake values for 1 
slice (nSUVAxMax1) for patients with grade 0, 2, or 3 esophagitis at the time of the PET study, A, 
grade 0, 2, or 3 maximum esophagitis grades, B, and nSUVAxMax1 grouped by patient 
progression of esophagitis grade at the time of the PET study to maximum grade, C. Boxplot 
corners represent 25th and 75th percentiles and middle line the median value. Outliers are 
denoted as ‘+’. 
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In the univariate analysis, most nSUV metrics were significantly correlated with 
esophagitis grade (p < 0.05) for the endpoints investigated (Table 5.2). The highest performing 
metrics for both endpoints were nSUVAxMax1 and nSUVLen40, with AUC values ≥ 0.85 for ≥ grade 
2 esophagitis at the time of the PET study and AUC values ≥ 0.91 for maximum esophagitis 
≥grade 2. SUVMean was associated only with ≥grade 2 esophagitis at the time of the PET study. 
SUVMax was significantly correlated (p < 0.05) with both endpoints, but performance was much 
lower than any significant normalized uptake metric (Table 5.2). 
The results of the multivariate analysis are listed in Table 5.3. Inclusion of only nSUV 
metrics for model features outperformed dose-only models for both ≥ grade 2 esophagitis 
endpoint scenarios (AUC 0.83 and 0.88 vs. 0.52 and 0.76, for grade at time of PET scan and 
treatment completion, respectively). The difference in AUC between model types was significant 
for both grade at time of PET scan (p<0.05) and treatment completion (p<0.001), respectively. 
Models that combined nSUV and dose metrics showed slight improvement in AUC, albeit with 
higher model complexity. In addition, nSUV metrics had higher model occurrence and lower 
penalization on average than dose metrics. 
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Table 5.2: Statistical analysis of the relationship between 18F-fluorodeoxyglucose (FDG) uptake 
metrics and esophagitis grade at the time of the FDG-positron emission tomography (PET) 
scan, and maximum treatment esophagitis grade (n = 79). Univariate logistic regression p-
values reported have been corrected with the Benjamini-Hochberg false discovery rate 
procedure. 
FDG uptake metric 
≥Grade 2 during PET scan ≥Grade 2 Treatment Maximum 
P Value  AUC* P Value  AUC* 
SUVmean 2.04E-02  0.67 2.35E-01  0.61 
SUVmax 5.23E-03  0.73 1.88E-03  0.75 
nSUVmean† 8.16E-05  0.84 4.09E-05  0.87 
nSUVmax 1.55E-04  0.82 1.26E-06  0.91 
nSUVaxMax1‡ 8.16E-05  0.85 1.17E-06  0.91 
nSUVaxMax3 5.32E-05  0.85 9.53E-06  0.87 
nSUVaxMax5 5.75E-05  0.84 1.52E-05  0.86 
nSUVaxMax7 8.16E-05  0.81 3.65E-05  0.84 
nSUVlen20** 5.32E-05  0.80 7.37E-06  0.89 
nSUVlen30 5.32E-05  0.84 1.17E-06  0.91 
nSUVlen40 8.16E-05  0.85 6.52E-08  0.92 
nSUVlen50 7.15E-04  0.81 1.26E-06  0.87 
nSUVlen60 1.32E-02  0.74 4.23E-05  0.80 
nSUVperc65†† 8.31E-05  0.83 1.12E-05  0.89 
nSUVperc75 8.31E-05  0.83 2.48E-06  0.90 
nSUVperc85 8.16E-05  0.84 2.48E-06  0.90 
nSUVperc95 4.69E-04  0.83 1.26E-06  0.91 
*Area under the curve. 
†Voxel mean normalized standard uptake value. 
‡Axial-averaged maximum nSUV for 1, 3, 5, and 7 slices (e.g., nSUVaxMax1 for the 1-slice average). 
**Axial length of esophageal tissue with at least a given percentage of axial-averaged nSUV response 
(e.g., nSUVlen20 for a length of esophagus with nSUV ≥ 20% axial-averaged response over the baseline 
SUV value). 
††Voxel percentile nSUV values from the sixty-fifth to the ninety-fifth percentiles (e.g., nSUVperc65 for the 
sixty-fifth percentile). 
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Table 5.3: Statistical analysis of the relationship between 18F-fluorodeoxyglucose (FDG) uptake 
metrics and maximum esophagitis grade (n = 79). P values reported have been corrected with 
the Benjamini-Hochberg false discovery rate procedure. 
FDG uptake metric 
Grade 2 Grade 3 
P Value 
Spearman 
coefficient AUC* P Value 
Spearman 
coefficient AUC* 
SUVmean 2.35E-01 0.17 0.62 3.13E-01 0.15 0.60 
SUVmax 1.88E-03 0.38 0.78 3.02E-02 0.33 0.71 
nSUVmean† 4.09E-05 0.50 0.86 1.44E-02 0.39 0.75 
nSUVmax 1.26E-06 0.56 0.91 1.41E-02 0.40 0.75 
nSUVAxMax1‡ 1.26E-06 0.56 0.90 4.43E-03 0.40 0.75 
nSUVAxMax3 9.53E-06 0.50 0.86 4.43E-03 0.45 0.78 
nSUVAxMax5 1.52E-05 0.50 0.86 4.43E-03 0.43 0.77 
nSUVAxMax7 3.65E-05 0.48 0.85 4.43E-03 0.41 0.76 
nSUVLen20**  7.37E-06 0.53 0.89 7.15E-03 0.37 0.73 
nSUVLen30 1.17E-06 0.56 0.90 4.43E-03 0.41 0.76 
nSUVLen40 6.52E-08 0.67 0.91 4.43E-03 0.43 0.77 
nSUVLen50 1.26E-06 0.57 0.86 7.15E-03 0.42 0.76 
nSUVLen60 4.23E-05 0.46 0.79 1.98E-02 0.38 0.72 
nSUVperc65†† 1.12E-05 0.53 0.89 3.57E-02 0.35 0.72 
nSUVperc75 2.48E-06 0.55 0.90 1.47E-02 0.37 0.74 
nSUVperc85 1.17E-06 0.56 0.91 4.43E-03 0.41 0.76 
nSUVperc95 1.26E-06 0.56 0.91 4.43E-03 0.45 0.79 
*Area under the curve. 
†Voxel mean normalized standard uptake value. 
‡Axial-averaged maximum nSUV for 1, 3, 5, and 7 slices (e.g., nSUVaxMax1 for the 1-slice average). 
**Axial length of esophageal tissue with at least a given percentage of axial-averaged nSUV response 
(e.g., nSUVlen20 for a length of esophagus with nSUV ≥ 20% axial-averaged response over the baseline 
SUV value). 
††Voxel percentile nSUV values from the sixty-fifth to the ninety-fifth percentiles (e.g., nSUVperc65 for the 
sixty-fifth percentile). 
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5.2.4 Normalized Uptake and Esophagitis Timing 
On average, symptoms were clinically reported after nSUV quantification. For all 26 
asymptomatic patients during the PET study that would develop ≥grade 2 esophagitis by 
treatment end (G0-2/3), esophagitis occurred a median of 6 fractions after the PET scan. For 
patients who had grade 2 esophagitis during the PET scan that became grade 3 esophagitis by 
the end of the treatment, the median time to onset was 7 fractions. 
 
5.2.5 Normalized Uptake to Predict Esophagitis Progression 
Figure 5.1C shows the difference in nSUV for the 2 asymptomatic patient groups during 
the PET study. Patients who eventually developed grade ≥2 esophagitis had markedly higher 
nSUV values during the PET study than those who did not develop esophagitis. The Mann-
Whitney U test showed differences in nSUV metric distributions between these 2 groups were 
significantly different (p < 0.05) for all nSUV metrics examined; differences in SUVMax or 
SUVMean were not significant. The performance of symptom progression models was AUCMean = 
0.67 and 0.75 for the dosimetric and nSUV-based models, respectively (Table 5.3). The 
combined features of dose and nSUV did not improve model AUCMean over nSUV-only models 
(0.72). The top recurring features were: nSUVLen30, nSUVLen40, and nSUVAxMax1 in both model 
types. 
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Table 5.3: LASSO regression multivariate analysis of nSUV metrics and ≥esophagitis grade 2 
(N=79), and the symptom progression prediction model construction from grade 0 esophagitis 
patients at time of the PET study (N=43) Using 3-fold cross-validation repeated for 100 
iterations. The median model order, mean AUC value with standard deviation, and the most 
prevalent recurring model features in the cross-validation process are listed. 
Feature 
Class 
Endpoint 
Model 
Order 
AUCmean* 
(S.D.) 
Top Recurring Predictors† 
nSUV** 
Mid-treatment ≥Grade 
2 
5 
0.83 
(±0.07) 
nSUVMean,nSUVLen30, nSUVAxMax3, 
nSUVLen20, nSUVAxMax1 
Treatment Max  
≥Grade 2 
4 
0.88 
(±0.05) 
nSUVLen40, nSUVMean, nSUVLen30, 
nSUVAxMax1 
DVH†† 
Mid-treatment ≥Grade 
2 
3 
0.52 
(±0.07) 
LE10100%, LE50100%, MED 
Treatment Max  
≥Grade 2 
3 
0.76 
(±0.12) 
Dmax, LE40100%, V50 
nSUV** & 
DVH†† 
Mid-treatment ≥Grade 
2 
6 
0.81 
(±0.07) 
nSUVMean, nSUVAxMax5, nSUVLen40, 
LE50100%, nSUVAxMax1 
Treatment Max  
≥Grade 2 
5 
0.91 
(±0.06) 
nSUVMean, LE50100%, nSUVLen40, 
LE30100%, nSUVLen30 
DVH†† 
Symptom Progression 
≥Grade 2 
3 
0.67 
(±0.13) 
Dmax, V30, LE30100% 
nSUV** 
Symptom Progression 
≥Grade 2 
3 
0.75 
(±0.10) 
nSUVLen30, nSUVLen40, nSUVAxMax1 
nSUV** & 
DVH†† 
Symptom Progression 
≥Grade 2 
4 
0.72 
(±0.12) 
nSUVLen30, nSUVLen40, nSUVAxMax1, 
LE40100% 
*Mean area under the curve from repeated cross-validation. 
†Dose and normalized uptake abbreviations defined in the methods section. 
**Normalized FDG uptake 
††Dose-volume histogram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
5.2.6 Normalized Uptake & Esophageal Expansion  
 The relationship between normalized FDG uptake and esophageal expansion both 
quantified at the same time during radiation therapy is shown for 67 patients in Figure 5.4. 
Patients have are identified by esophagitis grade for both esophagitis at time of quantification 
(Figure 5.4a), and esophagitis maximum treatment grade (Figure 5.4b). MaxExp1 and 
nSUVAxMax1 expansion and FDG metrics were statistically correlated with a Pearson 
coefficient of 0.66. An approximately linear correlation between MaxExp1 and nSUVAxMax1 is 
observed. Additionally, for both timings of esophagitis grade a strong stratification of toxicity 
and both metrics values is observed. 
 
 
Figure 5.4: Esophgeal expansion (MaxExp1) and FDG uptake (nSUVAxMax1) values for 67 
patients with grade 0, 2, or 3 esophagitis at the time of the PET study (A), and maximum 
esophagitis grades (B). 
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5.3 Chapter Discussion 
In this chapter, we demonstrate that FDG uptake is a radiation-response imaging 
biomarker that can be used as an objective quantification of esophagitis during radiation 
therapy for NSCLC. In addition, it is shown that FDG uptake can predict symptom progression 
for asymptomatic patients at the time of the PET study. The goal of this chapter was to develop 
an in-vivo method of quantifying esophagitis that provides spatial information about the 
specific location and extent of injury. We accomplished this by deriving localized metrics of 
normalized uptake from PET studies performed during radiation treatment and establishing the 
relationship between these metrics and esophagitis grade. 
Previous studies have shown that FDG uptake can quantify normal tissue response in 
lung for patients with NSCLC and esophageal cancer.44-49 Nijkamp et al also examined the use 
of post-treatment FDG-PET studies to quantify esophageal injury from radiation therapy.50 
Lyman-Kutcher-Burman models were created with and without FDG uptake to predict 
esophageal injury, and these models showed that prediction was improved by adding PET 
information to the dose-response model.58 Another study showed an increase in FDG uptake at 
6 discrete points along the length of the esophagus, with uptake normalized to the aortic 
arch.75 In another study, it was shown that the change in the 95th percentile of SUV of the 
esophagus from pre-treatment to weeks 2,4, and 7 of chemoradiotherapy is correlated to 
esophagitis using rigid PET image alignment, for 27 patients.76 However, these previous studies 
did not describe uptake in terms of esophagus geometry or conduct prediction modeling for 
symptom progression. In addition, various metrics with localization of response were not 
derived and tested in a multivariate analysis.  
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FDG uptake was normalized to the < 5Gy region of irradiated esophagus to reduce 
inter-patient variability of SUV. Standard SUVMean and SUVMax were not able to stratify or predict 
the progression of esophagitis. The choice of normalization has been utilized in studies of 
radiation-induced lung toxicity using FDG-PET.44-49 Another study used change in FDG-PET 
SUV during radiation therapy relative to pre-treatment status.76 Since pre-treatment FDG-PET 
studies acquired in the treatment position were not available for our patient cohort, this 
normalization method was not feasible.  
Normalized uptake metrics performed well in classifying not only esophagitis grade at 
the time of the PET scan, but also maximum esophagitis grade. Combining multiple nSUV 
metrics in logistic regression models to classify esophagitis did not substantially improve AUC 
value over using a single nSUV metric. DVH metrics alone performed poorly in classifying 
esophagitis grade. When DVH metrics were combined with nSUV metrics, AUC improved 
slightly for only the ≥grade 2 treatment maximum endpoint. In addition, nSUV metrics were 
chosen with higher frequency than DVH metrics in the nSUV/Dose-combined model 
construction. This shows the robustness of a single nSUV metric to quantify esophagitis. 
In addition to classifying esophagitis, the normalized uptake has the ability to predict 
symptom progression from patients that have grade 0 esophagitis at the time of the PET study. 
The ability of the LASSO models to predict if a patient will become ≥ grade 2 esophagitis by 
treatment completion was greater for nSUV-only models than DVH-only models, or the 
combined nSUV and DVH metric models, as quantified by the cross-validated AUCMean. The 
combined nSUV and DVH metric models outperformed the DVH-only models, with nSUV 
metrics chosen with higher frequency. The cross-validated AUCMean of 0.75 could potentially be 
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improved with a larger sample size and increase standardization of CT/PET scan acquisition and 
processing. In the realm of radiation oncology, preemptively identifying patients that will 
become symptomatic may allow for preemptive interventions (e.g. change in diet, anti-
inflammatory medicine, radioprotectors), that may help reduce adverse effects from therapy, 
thereby improving patient quality of life and preventing costly interventions (e.g., feeding tube, 
hospitalization). In addition, the comparison of nSUV and DVH models shows normalized 
uptake is providing unique response information we cannot obtain from the DVH. 
The timing of esophagitis symptoms and normalized uptake magnitude showed that 
increased uptake occurs before presentation of clinical symptoms. This supports the use of FDG 
uptake as a preemptive diagnostic tool for esophagitis development. Although the current 
study was conducted in patients with radiation-induced esophagitis, it may be possible to 
extend this methodology to other types of esophagitis. 
In chapter 3, the esophageal swelling on CT scans were shown to be a robust, objective 
measure of radiation esophagitis. Interestingly, the highest performing CT-based expansion 
biomarkers were based on axial maximum expansion (MaxExp1) and esophageal length with 
expansion greater than 30% (LenExp30%), which is consistent with the results of the nSUV 
metrics. The performance of normalized uptake and esophageal expansion metrics most 
correlated to the ≥grade 2 treatment maximum esophagitis endpoint were similar with AUC 
values above 0.90. Furthermore, this chapter showed there is a strong correlation between 
expansion and FDG biomarkers. One difference in the analyses of chapter 3 and the work in this 
chapter was the metric sampling frequency; weekly for expansion and once during treatment 
for normalized uptake. Normalized uptake’s classification performance could potentially be 
77 
 
increased by sampling multiple times during treatment. Because swelling is an inflammatory 
response, it is feasible that this method could be applied to other forms of esophagitis for 
detection and quantification of injury.  
Our study had limitations. Because only 1 PET scan was acquired during radiation 
treatment, the change of normalized uptake throughout treatment, including normalization 
value, could not be quantified for individual patients. Therefore, it is uncertain how early in 
radiation treatment quantification of esophagitis may be achievable using FDG uptake. 
However, several symptomatic patients did have large responses at fraction 18 (36 Gy delivered 
prescription dose). In addition, specification of normalized uptake magnitude and the onset of 
symptoms were skewed for patients who already had esophagitis symptoms at the time of the 
PET study. Another limitation is the frequency of esophagitis scoring. Esophagitis was scored at 
the weekly radiation oncology symptom clinic, which introduces uncertainty when trying to 
establish time differences between uptake magnitude and esophagitis severity. In addition, 
esophagitis scoring is a subjective process and other endpoints may be examined as well (e.g. 
weight loss, patient reported outcomes, etc.).   
 In conclusion, FDG-PET can be used to quantify esophagitis during radiation therapy. 
This quantification is noninvasive and objective, and also provides spatial information about the 
location and extent of esophageal injury which may be useful for studying esophageal dose-
response, specifically with the inclusion of spatial information. Normalized uptake is a patient-
specific radiation response that can predict whether patients who are asymptomatic at the time 
of the PET study may develop symptoms by the end of radiation treatment.   
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Chapter 6 
 
Influence of Dose-Geometry on Esophageal Expansion 
 
 
In previous chapters, esophageal expansion was established as a radiation-response 
biomarker and a surrogate endpoint of esophageal toxicity. This chapter uses the expansion 
biomarker to probe if dose-geometry influences esophageal-response. Esophageal regions with 
the highest radiation therapy plan dose were analyzed by examining the standard deviation of 
voxel dose across each cross-sectional slice of the sub volume, for each patient. Any correlation 
between the expansion biomarker and the spatial distribution of voxel dose across the 
esophageal slices is examined. This analysis is executed by examining the esophageal sub 
volume near the maximum axial esophagus dose, for any one slice, for a region of 9 esophageal 
slices (constant region volume) and the region with slices receiving at least 90% of the single 
maximum axial esophagus slice dose (region with similar axial esophagus dose).   
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6.1 Methods and Materials 
6.1.1 Patient Population 
The patient population for project 3.1 is the same cohort as those in chapters 3 and 4 
(projects 1.1 and 1.2). Eighty-five patients were selected from a prospective clinical trial at 
University of Texas-MD Anderson Cancer Center for stage III NSCLC, treated with concurrent 
intensity-modulated radiation therapy and chemotherapy (paclitaxel and carboplatin), with 
tumor prescription doses of 60 (n=4), 66 (n=28), or 74 (n=53) Gy in 2-Gy fractions over 6-8 
weeks. Patients had weekly 4DCT imaging and esophagitis scoring according to Common 
Terminology Criteria for Adverse Events version (CTCAE) 3.0. The distribution of maximum 
esophagitis grades during treatment was: 24 were grade 0, 45 were grade 2, and 16 were 
grade3. Since asymptomatic diagnostic assessment of esophagitis was not conducted, there 
were no grade1 patients in this study.  We selected 85 of 97 possible patients from this clinical 
trial for the present study, excluding 3 patients due to image quality and 9 for not having 4DCT 
imaging. Our study was approved by the University of Texas-MD Anderson Cancer Center 
Institutional Review Board and we complied with HIPAA regulations. 
CT scans were acquired on the same scanners using identical protocols as described in 
previous chapters. Patient treatment planning and segmentation was conducted using the 
Pinnacle treatment planning system (Phillips Healthcare), with esophageal contours segmented 
from the cricoid cartilage to the gastroesophageal junction, in the axial plane, with Pinnacle 
version 9.8.  
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6.1.2 Dose-Geometry Quantification 
 The scientific question investigated in this chapter is: what influence, if any, does dose-
geometry have on the expansion-response mechanism. Dose-geometry in this context is 
considered the conformity of the dose distribution across the cross-sectional area of a given 
axial slice of the esophagus. A comparison of differing dose-geometries for a single axial slice 
of the esophagus is illustrated in Figure 6.1. In this figure, the deviation of dose across the 
esophgeal slice is markedly different between the two representations. Figure 6.1B shows a 
partial sparing of dose for the given slice. This work examines if these differences in dose 
conformity yields significantly different observed esophageal expansion. The expansion-
response allows a precise quantification to test if differing dose-geometries can spare the 
esophagus.  
 
  
 
Figure 6.1: Plot of voxel dose within the esophagus in the axial plane for two different example 
dose conformities. The dose-geometry in (A) is more uniform, when compared to (B), which has 
a partial-sparing of dose towards the lateral end of the esophagus. 
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To examine any influence of dose-geometry on expansion-response, a robust measure 
of dose-geometry needs to be utilized. We summarize dose-geometry based on two principal 
quantities: the mean dose to the slice and the variation of dose across the slice. Dose-geometry 
was quantified by first calculating mean axial dose to each slice, for every slice, within the 
analyzed sub volume of the esophagus, individually for each patient. Next, the standard 
deviation of voxel dose across the cross-sectional area of the esophgeal slice was quantified for 
all slices in the analysis region. The standard deviation of dose is used as the representation of 
dose variation across a given slice of the esophagus. These two dose quantities are also 
examined in proportion to each other as the ratio of mean slice dose to standard deviation of 
dose across the given slice throughout this chapter. This arises from the fact that the 
expansion-response depends on the mean dose to the axial slice, yet the influence of dose 
deviation across the slice is being studied in this chapter. To put this into context, what if two 
slices had the same deviation of dose across each slice (dose-geometry), yet the mean doses 
were greatly different? It would follow that the slice with a larger mean dose would have a 
larger expansion-response, but this would not be a consequence of the dose-geometry. 
Additionally, this allows for analysis using a single metric instead of a combination of metrics.  
Dose-geometry is analyzed with two different types of analysis regions for this work. 
The attractiveness of using expansion as a response quantification, is its ability to localize the 
response. Therefore, we can discard much of the study patient’s esophagus from the analysis, 
only considering regions were response physically occurs. A question of how to choose the 
subregion of analysis naturally arises: should the region be dose dependent, or should the 
region be volume dependent, as both region types may effectively be different size and could 
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yield different results. Therefore, the esophageal subregion of analysis can either be volume 
constant, or dose constant. This work considers both subregion types in separate analyses, 
which are described in-depth in the following sections.  
  
6.1.3 Analysis of Constant Volume of Esophagus 
 To hold the volume of the region of analysis approximately constant, the response from 
a given patient’s dose-geometry was analyzed in a 9 slice region of the esophagus, centered on 
the axial slice with the highest axial dose. Dose-geometry, as quantified according to the 
previous section, was compared to the axially-averaged expansion in this 9 slice region of the 
esophagus. Each patient’s axial expansion was quantified at the given treatment week with 
maximal expansion. Variation of voxel dose across each slice in the analysis region is compared 
to the corresponding slices’ axial-average expansion. This expansion metric is the MaxExp9, as 
defined in chapter 3. While the MaxExp1 was shown to be the most robust measure of 
esophageal radiation response compared to toxicity, using MaxExp9 provides multiple data 
points of expansion and dose-geometry for a given patient, while not sacrificing the expansion 
and toxicity relationship, since MaxExp9 was highly correlated to esophagitis grade. In addition, 
using the 9 slice region allows for uncertainties associated with expansion and dose to be 
quantified in the superior-inferior direction along the esophagus, not just the axial plane, to be 
considered in the analysis.  
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6.1.4 Analysis of High-Dose Region of Esophagus  
 While the previous analysis holds the volume of analysis approximately constant, 
the expansion-response from a region with similar axial-averaged dose should also be 
examined. Potentially, a partial-sparing may be affected from regions with significantly 
different mean axial doses, and this must be held constant in a thorough analysis. 
Therefore, the high-dose analysis region of the esophagus was defined as all slices with 
a mean axial dose of at least 90% of the single maximum axial slice for a given patient.  
An example of the high-dose region of analysis is illustrated for an example patient in 
Figure 6.2. From this figure, the difference in response within slices receiving similar 
mean doses is shown in the red circled area. This analysis examines if variation in dose 
across the esophageal slices can explain the differences in slice expansion. 
All slices considered in the analysis must form a connected region with the axial 
slice that has the maximum mean slice dose. The axially-averaged expansion from each 
of these slices from the high-dose region is then compared to the corresponding 
standard deviation of dose across each slice within the analysis region. Each patient’s 
axial expansion was quantified at the given treatment week with maximal expansion. 
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Figure 6.2: Plot of axial expansion and corresponding axial dose for all slices of the esophagus 
at the week of maximal expansion for a single patient (gray circles). The red circled region 
represents the slices that comprise the high-dose region in the constant dose analysis of dose-
geometry. 
 
6.1.5 Statistical Analysis 
 Individual patient’s slice-based dose-geometry and corresponding slice expansion was 
examined using Spearman rank analysis. For each patient, the individual esophageal slice’s dose 
deviation, as quantified by the slice’s mean axial dose divided by the standard deviation of 
voxel dose, and the corresponding esophageal slice’s axially-averaged expansion value were 
paired together for every slice in the analysis region and compared with the Spearman rank 
correlation coefficient. This test was carried out for both the constant volume region of the 
esophagus and the high-dose region analyses, independently for each patient. Any 
dependence of expansion on dose-geometry would therefore be analyzed on an individual 
patient basis. 
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 The patient population was then analyzed collectively for correlation of the esophageal 
region mean expansion and the region’s dose-geometry. This analysis was conducted for both 
the high-dose region and the constant volume region, independently. Spearman correlation 
coefficients were calculated between mean regional dose, standard deviation of regional dose, 
the ratio of regional mean dose to the regional standard deviation of dose, the region mean 
expansion value, and the maximum esophagitis grade. The ratio of regional mean dose to the 
regional standard deviation of dose is analogous to the ratio of mean slice dose to standard 
deviation of dose across the slice, except in this metric dose and standard deviation of dose is 
quantified for the analyzed volume of esophagus. Linear models of dose-geometry using mean 
regional dose, standard deviation of regional dose, and the ratio of mean slice dose metrics, 
were covariates to fit regional mean expansion value. The goodness-of-fit metric was used to 
assess model fit. Statistical significance of linear model variables was test with a t-test at the 
p<0.05 significance level. 
 
6.2 Results 
6.2.1 Patient-Specific Slice-based Dose-Geometry  
 Spearman correlation coefficients of axial-averaged expansion and 
corresponding dose deviation for each esophageal slice within a specific patient’s 
analysis region is shown in Figure 6.3 for the analysis region of constant volume and 
analysis region of similar slice dose, respectively. The Spearman rank coefficients show 
a correlation between slice-based expansion and corresponding dose deviation for 
some patients. However, this effect is inversely proportional in many patients. 
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Moreover, the majority of patients had correlation coefficients in the range of (-0.5, 0.5), 
shown by the gray shaded region in the figure, and indicates poor correlation of dose-
geometry and slice expansion. This trend is observed for both analysis region types. 
 
Figure 6.3: Plot of Spearman correlation coefficient of axially-averaged expansion and the ratio 
of mean slice dose to standard deviation of dose across a given slice, for all slices in the high-
dose region of analysis (A), and the 9 esophageal slice region of analysis (B), for every individual 
patient grouped according to maximum esophagitis grade. The gray shaded region represents 
coefficients in the range of (-0.5,0.5). 
 
 
6.2.2 Population-based Dose-Geometry  
 Figure 6.4 shows the relationship of dose-geometry to expansion for the constant 
volume region analysis, for patients that had either maximum grade 0 or grade 3 esophagitis 
during radiation therapy and mean region dose of at least 25 Gy. From this figure, an overlap of 
grade 0 and grade 3 patients with similar mean regional doses can be observed. A similar trend 
exists with constant dose region analysis. The Spearman correlation analysis is summarized in 
Figure 6.5 for both region types analyzed. The highest Spearman coefficient of any dose 
variable to any outcome was 0.495 for mean regional dose and ≥ grade 2 esophagitis, for the 
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constant-dose region.  The highest Spearman coefficient of any dose variable to any outcome 
was 0.496 for mean regional dose and mean regional expansion, for the constant-volume 
region. In both analysis region types, the ratio of mean regional dose to standard deviate 
on of dose had Spearman coefficients of less than 0.400 for any of the three outcomes.  
 
 
Figure 6.4: Plot of mean regional dose and mean regional expansion for the 9 slice analysis 
region for 11 grade 0 patients (black squares) and 16 grade 3 patients (red squares). The 
vertical bars represent each patient’s standard deviation of axial expansion. The horizontal bars 
represent the standard deviation of dose in the analysis region. 
88 
 
Figure 6.5: Plot of self-correlation matrix of Spearman correlation coefficients for ≥grade 2 and 
grade 3 esophagitis, region mean expansion value, region mean dose value, the mean standard 
deviation of axial dose, and the ratio of region mean axial dose to the corresponding standard 
deviation of dose, for the high-dose region of analysis (A), and the 9 esophageal slice region of 
analysis (B). Color shade represents the Spearman correlation coefficient value, as given by the 
corresponding color bar, between the corresponding variables for the row/column 
combination.  
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 Results of the linear model of expansion and dose-geometry are displayed in Table 6.1. 
The goodness-of-fit metric was 0.107 and 0.153 for the constant dose and constant volume 
regions of analysis, respectively.  Neither standard deviation of regional dose nor the ratio of 
mean regional dose to the standard deviation of dose was significant in either linear model. The 
only significant coefficient in either region type linear model was the mean regional dose for 
the constant volume region of analysis.   
 
Table 6.1: Linear model of expansion in the analysis region, with mean regional dose, standard 
deviation of regional dose, and the ratio of mean regional dose to standard deviation of dose, 
as the respective covariates, from all 85 patients. The upper table represents the region of near 
constant dose and the lower table represents the 9 slice volume region of analysis. 
High-Dose Region Coefficient SE tStat p-value 
Intercept 33.05 20.28 1.63 0.107 
Mean Dose 0.50 0.27 1.85 0.068 
Stdev Dose -1.07 1.29 -0.83 0.410 
Dose/Stdev 0.14 0.26 0.54 0.589 
Constant-Volume Region Coefficient SE tStat p-value 
Intercept 9.32 12.40 0.75 0.455 
Mean Dose 0.73 0.21 3.38 0.001 
Stdev Dose -0.66 0.90 -0.73 0.465 
Dose/Stdev -0.10 0.27 -0.36 0.717 
 
 
90 
 
6.2 Chapter Discussion 
 This project was designed to elucidate any dependence of expansion on dose-geometry 
with the hypothesis that a higher standard deviation of dose across the cross-sectional area of 
a given slice of the esophagus will provide a partial sparing effect, thereby reducing expansion 
for an increasing standard deviation of dose.  
 The effect of varying dose across a given axial slice of the esophagus did show a 
decrease in expansion for some patients, for slices examined in the volume with all slices of at 
least 90% of the maximum axial-averaged dose (constant dose analysis region). This was also 
observed for some patients in the 9 slice volume centered on the slice with the maximum axial-
averaged dose (constant volume analysis region). However, most patients did not show a 
correlation of decreasing expansion for a corresponding increase in dose deviation. 
Additionally, some patients observed the opposite effect where dose deviation across 
esophageal slices had an accompanying increase in the slice expansion.  
 The population-based analysis averaged the expansion and dose, as well as dose 
deviation across the axial slices, from all slices in the analysis region (for both analysis region 
types). This summarized the expansion and dose-geometry for individual patients and then 
combined them into a single cohort to examine the entire population. In this analysis, 
Spearman rank correlation did not show a strong influence of dose-geometry on expansion. In 
addition to expansion, esophagitis grade was also examined as a response. Similar to 
expansion-response, dose-geometry did not show a strong correlation to esophagitis grade. 
This should be expected given the strong relationship to maximum expansion of one axial slice 
of the esophagus (MaxExp1) and esophagitis grade, as shown in Chapter 3. The linear models 
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of dose-geometry with expansion had poor goodness-of-fit metrics, with both region types 
having R2 of less than 0.160 in either case. Furthermore, as illustrated in Figure 6.4, there is no 
clear partial sparing effect of increasing axial dose-deviation in either grade 0 or grade 3 
patients. The expectation would be that if dose-geometry can reduce expansion, there should 
be an observed trend of grade 0 patients with large dose-deviation compared to grade 3 
patients with small dose-deviations, for similar mean doses for the analysis region. However, we 
see an opposite effect; many grade 3 patients have larger dose-deviations than grade 0 
patients of similar mean region dose.  
 This study was not without limitations. Dosimetric accuracy is of primary concern when 
examining voxel dose in an organ that has a small cross-sectional area, such as the esophagus. 
This is especially true in our study as axial slices of the esophagus and the corresponding 
deviation of dose across the slice was this study’s focus. To reduce uncertainty associated with 
dose calculation, we accumulated dose on weekly 4DCT study’s and then deformed the 
calculated weekly dose back into the plan 4DCT frame of reference and summed all weekly 
doses. Another limitation is the uncertainty in expansion. While expansion allows study of sub 
volumes of the esophagus to localize radiation response, it does have uncertainty associated 
with its calculation. It is possible that the individual patient-specific analysis of dose-geometry 
may require a level of precision not attainable presently. However, the population-based 
analysis showed no influence of dose-geometry on expansion that is clinically useful.  
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 In conclusion, dose-geometry does not have a clinically detectable influence on 
radiation response in the esophagus. The amount of variability in dose-deviation, mean 
regional dose, and corresponding expansion shows dose-geometry is not influential for 
esophageal response. 
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Chapter 7 
 
Influence of Modality on Esophageal Expansion and FDG Uptake: 
IMRT versus Proton Therapy  
 
 
In the previous chapter, the esophageal expansion biomarker was utilized to examine if 
radiation dose-geometry was influential on radiation response. In this chapter, the question of 
radiation treatment modality having an influence on radiation-response and toxicity in the 
esophagus is addressed. First, the most robust expansion and normalized uptake biomarkers 
are identified for patients receiving passive scatter proton therapy (PSPT), using the same 
methodology as in chapters 3 and 5. Next, the dose was compared between IMRT and PSPT 
patients for the study population. Additionally, dynamics of biomarker and toxicity response 
were examined throughout treatment between the two modalities. Any influence of modality 
on expansion was investigated with a cross-validated Random Forests regression model. Finally, 
modality’s impact on toxicity prediction modelling was examined with LASSO logistic 
regression. 
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7.1 Methods and Materials 
7.1.1 Patient Population 
It is important to note that two separate cohorts are being analyzed in this chapter. One 
cohort consists of patients analyzed using the FDG-based biomarker response (n=79), and the 
other cohort being patients analyzed using esophageal expansion-based biomarker response 
(n=134). A total of 68 patients were in both the FDG and expansion cohorts. The FDG-based 
cohort is identical to the cohort studied in chapter 5. The expansion-based patient cohort for 
this chapter (project 3.2) contains the same cohort as those in chapters 3 and 4 (projects 1.1, 
1.2, 2.1 and 2.2), but 49 additional patients treated with passive-scatter proton therapy (PSPT) 
are also included in this project’s study cohort.  
All patients were selected from the prospective clinical trial at University of Texas-MD 
Anderson Cancer Center for stage III NSCLC, described in previous chapters. Esophagitis scoring 
was conducted in accordance to Common Terminology Criteria for Adverse Events version 
(CTCAE) 3.0. The demographics and distribution of maximum esophagitis grades during 
treatment for patients in the expansion and FDG-PET analyses are listed in Tables 7.1 and 7.2, 
respectively. Our study was approved by the University of Texas-MD Anderson Cancer Center 
Institutional Review Board and was compliant with HIPAA regulations. 
As described in previous chapters, CT scans were acquired on General Electric 
Lightspeed Discovery ST or Lightspeed RT16 (GE Healthcare, Waukesha, WI) or Philips Brilliance 
64 (Philips Healthcare, Bothell, WA) CT scanners operated at 120 kV. Voxel dimensions were 
0.98x0.98x2.50 mm in the right-left direction, anterior-posterior, and superior-inferior direction, 
respectively, with a 512×512-pixel area. Patient treatment planning and segmentation was 
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conducted using the Pinnacle treatment planning system (Phillips Healthcare), with esophageal 
contours segmented from the cricoid cartilage to the gastroesophageal junction, in the axial 
plane, with Pinnacle version 9.8.  
 
Table 7.1: Demographics of patients from the expansion analyses (n=134). 
Characteristic Datum Proton IMRT 
Median age (range)    
All 66 (38-85) 67 (38-76) 65 (43-85) 
Male 66 (43-85) 68 (57-76) 65 (47-80) 
Female 65 (38-80) 65 (38-75) 66 (43-85)  
Sex    
No. of Males 75 30 45 
No. of Females 59 19 40 
Histologic findings    
Squamous cell carcinoma 47 18 29 
Adenocarcinoma 75 25 50 
Large cell carcinoma 5 2 3 
Other 7 4 3 
Smoking history    
Current smoker 44 26 18 
Former smoker 79 21 58 
Never smoked 11 2 9 
Stage    
IIa 5 2 3 
IIb 9 6 3 
IIIa 59 20 39 
IIIb 56 20 36 
IV 5 1 4 
Treatment dose, Gy    
74 88 35 53 
66 38 10 28 
60 8 4 4 
Maximum Esophagitis  
    Grade 
   
Grade 0 33 9 24 
Grade 2 95 49 46 
Grade 3 26 11 15 
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Table 7.2: Demographics of patients from the FDG-PET normalized uptake analyses (n=79). 
Characteristic Datum Proton IMRT 
Median age (range)    
All 66 years (38-80 years) 66 66 
Male 65 years (51-79 years) 68 65 
Female 66 years (38-80 years) 62 68 
Sex    
No. of Males 46 20 26 
No. of Females 33 11 22 
Histologic findings    
Squamous cell 
carcinoma 
31 10 21 
Adenocarcinoma 41 15 26 
Large cell carcinoma 3 1 2 
Other 4 3 1 
Smoking history    
Current smoker 27 15 12 
Former smoker 46 15 31 
Never smoked 6 2 4 
Stage    
IIa 3 2 1 
IIb 5 3 2 
IIIa 29 11 18 
IIIb 38 14 24 
IV 4 1 3 
Treatment dose, Gy    
74 46 19 27 
66 28 9 19 
60   4 
Maximum Esophagitis  
    Grade 
   
Grade 0 14 6 8 
Grade 2 36 16 20 
Grade 3 21 9 12 
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7.1.2 Proton Treatment Radiation Response and Toxicity 
 This chapter seeks to determine if response, whether quantified with expansion or FDG-
uptake, differs based on the type radiation therapy modality used for treatment (IMRT or 
Proton therapy). Therefore, the differences in radiation dose must be analyzed between the 
treatment modality subgroups. This is to ensure that if there exists a difference in response, it 
can be elucidated whether the variation in response is caused by discrepancy in treatment dose 
or because there is an inherent difference in esophageal response of radiation treatment from 
protons or photons.  
The dosimetric differences were analyzed between patients treated with PSPT or IMRT. 
The Kruskal-Wallis analysis of variance (ANOVA) was utilized to test any significant difference 
(p<0.05) between dose metrics in the form of: equivalent uniform dose (EUD), maximum 
esophagus dose (Dmax), mean esophageal dose (MED), and V20 to V70, in 10 Gy increments. 
This was carried out separately for both expansion and FDG analyses cohorts. To determine the 
appropriate scaling parameter to calculate EUD, Lyman-Kutcher-Burman (LKB) models were fit 
to the expansion and FDG-PET cohorts for a grade 3 complication endpoint, in separate 
models, to determine the slope of the sigmoid curve, the dose of 50% complication, and the 
volume parameter of the corresponding LKB model. These derived parameters were then used 
to calculate equivalent uniform dose for the corresponding study cohort. 
For the expansion cohort, the correlation of radiation-response biomarkers and 
esophagitis grade was analyzed for the 49 proton patients. This is a repeat of the analysis 
conducted in chapter 3, where univariate logistic regression and AUC were calculated to 
identify the highest performing expansion metrics for patients receiving IMRT. Spearman rank 
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coefficients and p-values (p<0.05 for significance after applying the Benjamini-Hochberg false 
discovery rate procedure) from univariate logistic regression were also calculated.  
The highest performing expansion and FDG-based biomarkers for both modality 
cohorts were compared. The Kruskal-Wallis ANOVA was used to test any significant difference 
in biomarker values between all patients grouped according to treatment modality. This was 
repeated for only patients that had ≥ grade 2 maximum esophagitis, and then again ≥ grade 3 
maximum esophagitis, in separate tests. The temporal dynamics of esophagitis and expansion 
biomarker value throughout treatment were also examined. 
 
7.1.3 Modality and Expansion Regression Modelling   
 To probe if modality influences expansion biomarker response in a multivariable 
analysis, Random Forests regression was utilized.  Repeated cross-validation was utilized to 
reduce bias and obtain a more generalizable modelling process for 1000 iterations of randomly 
drawn data folds consisting of training and test sets in a respective 70%/30% split of the patient 
cohort. This model construction process is identical to that utilized in chapter 4, with the 
exception of solving a regression and not a classification problem. Additionally, the minimum 
observation per leaf was set to 5 and the number of randomly drawn predictors at each node is 
16 (the number of predictors divided by 3).  Model predictors consisted of clinical (tumor stage, 
tumor location, histology, gender, age, and smoking status) and dosimetric factors (Dmax, MED, 
esophagus EUD, V10-V70 in 5Gy increments, LE10-LE60, in 10 Gy increments for 25% and 100% 
axial esophagus coverage). These are the same model predictors described with more detail in 
chapter 4.    
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Model calibration is assessed with the goodness-of-fit metric on the training set 
between model-calculated and known expansion values. To assess model predictive 
performance, the root mean squared error (RMSE) was calculated on the test sets from model-
computed and known expansion values. The model construction process was first executed 
without modality as a predictor and model performance was assessed. Next, modality 
information was included as a model predictor; the performance was assessed, and then 
compared to the models constructed without modality information as a model predictor. 
Modality predictor influence in the constructed models was computed with the out-of-bag 
permutation error. This allows predictors to be ranked in terms of importance in the model.  
 
7.1.4 LASSO NTCP Modelling and Modality 
 In chapter 4, multiple machine learning methods were utilized to create NTCP models 
for esophageal toxicity. This section uses the same LASSO logistic regression implementation as 
found in chapter 4, with prediction models created with and without modality as a predictor 
(dichotomous 1 or 0 indicating PSPT or IMRT modality, respectively). The same repeated cross-
validation procedure is utilized for 1000 iterations of randomly drawn training and test data 
folds, with stratification. The models are constructed to classify the ≥ grade 3 esophagitis 
endpoint in both model types. Model calibration and predictive performance is assessed with 
AUC on the training and test sets, respectively. To quantify predictor importance, the most 
common recurring predictors in individual models were cataloged for each iteration of model 
construction. 
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7.2 Results 
7.2.1 Modality, Radiation Response, and Toxicity  
 Overall, DVH dose metrics were similar between modality for both expansion and 
normalized uptake cohorts. Figure 7.1 illustrates the distribution of patient DVH metrics 
between modality for both biomarker type. For both analyses, the distributions of DVH metrics 
for patients that develop grade 3 esophagitis are displayed in Figure 7.2. 
 The equivalent uniform dose calculation parameters derived from the LKB models were 
consistent for both the expansion and FDG-PET cohorts. The volume parameter was determined 
to be 0.33 for both cohorts, which is consistent with other LKB models of esophagitis in the 
literature.32, 50, 77,78 
 For patients treated with PSPT, we observe higher dose-volume in the expansion cohort, 
with similar mean and max doses. The difference between dose-volume was greatest among 
patients that develop grade 3 esophagitis (Figure 7.2). This difference was shown to be 
statistically significant for V20 to V60, for the grade 3 patient group. Neither EUD, Dmax, nor 
MED showed significant differences in any patient complication group from the expansion 
analysis. Results of the statistical tests are shown in Table 7.3.  
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Figure 7.1: Boxplots of the distribution of esophageal equivalent uniform dose and DVH 
metrics for the expansion analyses (A,B) and the normalized uptake analyses (C,D). The gray ‘+’ 
represent outliers, the box vertical edges represent the 25th and 75th quartiles, the solid line in 
each box represents the corresponding median value, the black circles within each box 
represents the corresponding mean metric value, and the whiskers represent the metric value 
ranges.  
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Figure 7.2: Boxplots of the distribution of esophageal equivalent uniform dose and DVH 
metrics for the expansion analyses (A,B) and the normalized uptake analyses (C,D) for patients 
that develop grade 3 esophagitis. The gray ‘+’ represent outliers, the box vertical edges 
represent the 25th and 75th quartiles, the solid line in each box represents the corresponding 
median value, the black circles within each box represents the corresponding mean metric 
value, and the whiskers represent the metric value ranges.  
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Table 7.3: p-values of Kruskal-Wallis ANOVA tests for DVH metrics between patients treated 
with PSPT and IMRT for the expansion biomarker cohort. Significance level is p<0.05, n=134. 
Kruskal-Wallis ANOVA (Dose-Expansion Patients) 
Endpoint 
EUD 
(Gy) 
Dmax 
(Gy) 
MED 
(Gy) 
V20 
(cc) 
V30 V40 V50 V60 V70 
All 0.085 0.928 0.224 0.315 0.125 0.130 0.180 0.197 0.639 
≥Grade 2 0.378 0.899 0.092 0.338 0.147 0.136 0.468 0.401 0.917 
≥Grade 3 0.844 0.693 0.076 0.026 0.030 0.016 0.002 0.030 0.960 
 
 
For the normalized uptake cohort analysis, DVH metrics were not significantly different 
for either the entire study group of patients or patients with grade 2 or grade 3 esophagitis 
complication. The results of the statistical tests are shown in Table 7.4. 
 
Table 7.4: p-values of Kruskal-Wallis ANOVA tests for DVH metrics between patients treated 
with PSPT and IMRT for the FDG-PET biomarker cohort. Significance level is p<0.05, n=79. 
Kruskal-Wallis ANOVA (Dose-FDG Patients) 
Endpoint 
EUD 
(Gy) 
Dmax 
(Gy) 
MED 
(Gy) 
V20 
(cc) 
V30 V40 V50 V60 V70 
All 0.240 0.783 0.633 0.900 0.928 0.759 0.222 0.716 0.175 
≥Grade 2 0.5491 0.983 0.526 0.780 0.672 0.983 0.175 0.865 0.119 
≥Grade 3 0.1166 0.764 0.570 0.483 0.243 0.483 0.241 0.780 0.151 
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 The dynamics of patient toxicity throughout treatment, separated by treatment 
modality, is presented for patients in the expansion biomarker analysis in Figure 7.3. The onset 
and proportionality of toxicity throughout treatment is similar for both treatment types. 
 
 
 
Figure 7.3: Stacked bar chart of distribution of esophagitis grade in 5 fraction time intervals 
throughout treatment for patients receiving IMRT (left) and PSPT (right), in the expansion 
biomarker analysis. Blue represents grade 0, green grade 2, and red represents grade 3 
maximum esophagitis grades.   
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 Similar to toxicity onset, expansion dynamics peak at the end of treatment and in a 
similar fashion. The patient MaxExp1 in 5 fraction time intervals is illustrated in Figure 7.4. 
 
 
 
 
Figure 7.4: Stacked bar chart of distribution of esophagitis MaxExp1 in 5 fraction time intervals 
throughout treatment for patients receiving IMRT (left) and PSPT (right), in the expansion 
biomarker analysis, with threshold expansion levels of 30%, and 50%. Blue represents ≤ 30%, 
green > 30%, and red represents > 50% MaxExp1.   
 
The results of the statistical analysis of the expansion biomarker and toxicity for the 49 PSPT 
patients are shown in Table 7.5. Similar to the IMRT patients, MaxExp1 and LenExp30% are the 
highest performing biomarkers. The Kruskal-Wallis test between expansion biomarker was then 
utilized on MaxExp1 and LenExp30%. There was significant difference in MaxExp1 for the ≥ 
grade 2 and ≥ grade 3 complication groups, for different treatment modality. This is illustrated 
in Figure 7.5.  LenExp30% showed significant difference in biomarker value between treatment 
modality in the ≥ grade 3 complication group. For normalized uptake, nSUVAxMax1 and 
nSUVLen40% were the highest performing FDG-based biomarkers. The Kruskal-Wallis test was 
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utilized for nSUVAxMax1 and nSUVLen40% and did not yield any significant difference between 
values in the IMRT and PSPT cohorts. The results of the Kruskal-Wallis tests for biomarker value 
between modality are shown in Table 7.6. 
 
Table 7.5: Statistical analysis of esophageal expansion biomarkers and esophagitis 
grade, for patients receiving PSPT (n=49). Rs is the Spearman rank correlation 
coefficient, P is the p-value, and AUC is the area under the curve from ROC analysis. 
Expansion 
Metrics 
≥Grade 2 ≥Grade 3 
AUC P Rs AUC P Rs 
MeanExp 0.831 0.002 0.444 0.819 0.004 0.429 
MaxExp1 0.869 <0.001 0.496 0.828 0.003 0.414 
MaxExp3 0.817 0.006 0.425 0.700 0.066 0.268 
MaxExp5 0.822 0.006 0.432 0.694 0.066 0.261 
MaxExp7 0.825 0.005 0.436 0.708 0.066 0.280 
MaxExp9 0.831 0.005 0.444 0.708 0.072 0.280 
MaxExp11 0.828 0.004 0.440 0.706 0.072 0.276 
LenExp20% 0.858 0.001 0.482 0.840 0.003 0.457 
LenExp30% 0.892 <0.001 0.565 0.863 0.003 0.469 
LenExp40% 0.875 <0.001 0.530 0.839 0.003 0.490 
LenExp50% 0.775 0.001 0.428 0.797 0.028 0.437 
LenExp60% 0.750 0.002 0.394 0.806 0.072 0.461 
LenExp70% 0.613 0.049 0.225 0.536 0.139 0.072 
LenExp80% 0.563 0.155 0.160 0.576 0.072 0.195 
LenExp90% 0.513 0.522 0.068 0.556 0.072 0.304 
LenExp100% 0.513 0.522 0.068 0.556 0.072 0.304 
PercExp60 0.800 0.002 0.403 0.847 0.003 0.466 
PercExp65 0.828 0.002 0.440 0.858 0.003 0.481 
PercExp70 0.839 0.001 0.455 0.844 0.004 0.462 
PercExp75 0.850 0.001 0.470 0.833 0.003 0.447 
PercExp80 0.856 0.001 0.477 0.814 0.003 0.421 
PercExp85 0.856 0.001 0.477 0.792 0.005 0.391 
PercExp90 0.861 0.001 0.485 0.797 0.005 0.399 
PercExp95 0.867 0.001 0.492 0.806 0.004 0.410 
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Figure 7.5: Boxplots of MaxExp1 for either IMRT (A) or PSPT (B) treatment modalities, grouped 
according to patient maximum esophagitis grade during treatment. Red ‘+’ indicate outliers, 
and box edges are the 25th and 75th quartiles. Whiskers represent range and the red line within 
the box represents the median value. 
 
 
 
Table 7.6: p-values of Kruskal-Wallis ANOVA tests for biomarker values between patients 
treated with PSPT and IMRT for the expansion (n=134) and FDG-PET (n=79) cohorts. 
Significance level is p<0.05. 
Kruskal-Wallis ANOVA 
 Expansion Normalized Uptake 
Endpoint MaxExp1 LenExp30 nSUVAxMax1 nSUVLen40% 
All 0.392 0.483 0.182 0.100 
≥Grade 2 0.049 0.093 0.182 0.100 
≥Grade 3 0.016 0.036 0.815 0.616 
EUD ≥ 32 Gy 0.131 0.455 0.828 0.713 
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The relationship between MaxExp1 biomarker value and esophageal equivalent uniform 
dose for the given treatment modality and esophagitis severity is shown in Figure 7.6. The 
relationship between expansion and dose in a 9 slice subvolume centered at the slice of 
maximal expansion for the given treatment modality and esophagitis severity is shown in Figure 
7.7. In either case, there exists no clear difference in dose-response between PSPT and IMRT. 
EUD does not show a strong delineation of toxicity severity for increasing EUD above 32 Gy. 
Below approximately 32 Gy, grade 3 esophagitis does not occur for either treatment cohort. 
However, after this dose level severity does increase but several grade 0 patients have similar 
EUD to grade 3 patients. We do see a strong separation of grade 0 and grade 3 patients around 
MaxExp1 equal to 50%. A similar dose and expansion-response trend is observed for the 
subvolume analysis. There is no severe toxicity until about 35 Gy and expansion discriminates 
between severe toxicity and patients that are asymptomatic, at around 40% mean subvolume 
expansion. Additionally, many patients that are asymptomatic have similar subvolume mean 
doses as patients who experience grade 3 esophagitis.  
The distribution of MaxExp1 for patients with esophagus equivalent uniform dose above 
32 Gy, grouped according to treatment modality, is shown in Figure 7.8. It is evident that the 
values of MaxExp1 have similar values near the median, regardless of treatment modality. 
Additionally, there was no significant different between treatment modality for either expansion 
or FDG-based biomarker values for patients within this dose range, according to the Kruskal-
Wallis ANOVA test. The results of the statistical tests are shown in the last row of Table 7.6. 
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Figure 7.6: Plot of MaxExp1 for a given esophageal EUD, with data points grouped according 
to treatment modality (‘O’ for IMRT and ‘X’ for PSPT), as well as maximum esophagitis grade 
during treatment (blue = grade 0, black = grade 2, and red = grade 3). 
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Figure 7.7: Plot of 9 slice subvolume mean expansion and mean dose for 134 study patients, 
with data points grouped according to treatment modality (‘O’ for IMRT and ‘X’ for PSPT), as 
well as maximum esophagitis grade during treatment (blue = grade 0, black = grade 2, and red 
= grade 3). 
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Figure 7.8: Boxplot of the distribution of MaxExp1 values for patients with esophageal EUD ≥ 
32 Gy, grouped according to treatment modality. The edges of the box represent the quartile 
values of expansion, with the red line within each box representing that groups median 
expansion value. The range of values is represented by the black whiskers and the red ‘+’ 
denotes outliers (values beyond 1.5 times the interquartile range from the edge of the box). 
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7.2.2 Expansion Random Forests Regression Modelling 
 The results of the calibration of Random Forests regression models, both with and 
without modality as a predictor variable, are shown in Figure 7.9A. A reasonable fit of the 
training is obtained with goodness-of-fit around 0.64 on average, for both model types. The 
predictive regression model performance is similar for both model types with and without 
modality as a predictor variable. This is shown in Figure 7.9B. The RMSE is similar for both 
model types with RMSE approximately 43% on average. The out-of-bag-permutation error 
ranked modality as 32nd out of 50 predictors in the modality predictor model types. This 
indicated modality is not influential in the response model.  
Figure 7.9: Boxplot of Random Forests regression models goodness-of-fit (A) and RMSE (B) of 
MaxExp1 for 134 patients. Modality indicates models were constructed with modality 
information as predictor variable. Red ‘+’ indicate outliers, and box edges are the 25th and 75th 
quartiles. Whiskers represent range and the red line within the box represents the median 
value. 
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7.2.3 LASSO NTCP Modelling and Modality 
 Results for the LASSO NTCP model construction procedure is listed in Table 7.7. For 
both model types with and without modality as a predictor the model fit and predictive 
performance were similar, as indicated by AUCTraining and AUCTest, respectively. The distribution 
of both metrics between either model types had similar standard deviations. Additionally, the 
highest recurring model predictors were nearly identical, with mean esophageal dose being the 
highest recurring predictor regardless of model type.  
 
 
Table 7.7: Results of the LASSO logistic regression NTCP model construction process for 49 
PSPT and 85 IMRT patients, for 1000 iterations of cross-validation. Models constructed with 
treatment modality as a predictor for ≥ grade 3 esophagitis are listed on the row titled 
‘modality’. The 5 highest recurring predictors from all iterations of the model construction 
procedure are listed from highest to lowest recurring. Standard deviation of AUC values are 
listed in parentheses. 
Lasso Classification of ≥ Grade 3 Esophagitis (n=134) 
Model Type AUCTraining (S.D.) AUCTest (S.D.) Recurring Predictors 
No modality 0.845 (±0.053) 0.727 (±0.087) 
MED, LE60100%, Tumor location, 
V60, Smoking Status 
Modality 0.843 (±0.051) 0.725 (±0.088) 
MED, LE60100%, V65, Smoking 
Status, Tumor Location 
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7.2 Chapter Discussion 
 In this chapter, the influence of treatment modality, whether from passive scatter proton 
therapy or photon-based IMRT, was addressed using the objective esophageal radiation 
response biomarkers. One of the purported benefits of proton-based radiotherapy over 
photon-based treatments is a reduction in normal tissue dose and thereby a reduction in 
normal tissue toxicity.79-87 This work utilizes the FDG and expansion biomarkers to probe what 
difference, if any, exists in observed response with photon or proton treatment. For the repeat 
analysis of expansion biomarkers and toxicity with the patients treated with proton therapy, the 
results were consistent with the analysis of the IMRT patients in chapter 3. Both MaxExp1 and 
LenExp30% were the highest performing biomarkers in terms of classifying esophagitis severity 
between either treatment modality.   
The FDG-based biomarkers first investigated in chapter 5 were reanalyzed by separating 
patients based on IMRT or PSPT treatment, to determine if there is any difference in FDG-
response for patients based on treatment modality. No significant difference was found for in 
the distribution of FDG-response for either the nSUVAxMax1 or nSUVLen40% biomarkers between 
patients treated with IMRT or PSPT. For both expansion and FDG-uptake response, this shows 
robustness between either imaging biomarker types and also verifies the initial analysis of the 
relationship between the biomarkers and toxicity found in chapters 3 and 5, respectively. 
 Comparison of dosimetric differences between modality cohorts showed some 
differences in the expansion biomarker patient group, with PSPT patients having higher dose-
volumes. While this was shown to have statistical significance, this did not show a difference in 
the timing of response or toxicity. The distribution of MaxExp1 for grade 3 patients showed a 
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smaller standard deviation and less extreme maximum values, while having similar population 
mean and median biomarker values. This difference in MaxExp1 response can be explained by 
the smaller sample size of the PSPT cohort compared to IMRT. Removing the three IMRT 
patients that had the most extreme MaxExp1 values within the grade 3 maximum esophagitis 
group made the distribution of MaxExp1 statistically similar to that of the PSPT patients (for 
Kruskal-Wallis test, the p-value becomes > 0.05). Furthermore, the previously identified 
MaxExp1 > 50% threshold as a surrogate for severe esophagitis is consistent between both 
modality cohorts. There was no significant difference in dose between modality cohorts in the 
FDG-based biomarker analyses.  
 The Random Forests regression modelling showed quite similar model fits regardless of 
whether or not patient modality information was included in the model construction process. 
The results of the goodness-of-fit show reasonable calibration for both model types. The 
similarity of the root mean squared errors from the independent test sets are similar for both 
model types. The RMSE values were approximately 43% on average in both modelling 
scenarios, indicating respectable model performance for a multivariate regression model.  
Furthermore, the regression models that included modality information did not benefit from 
treatment type as a predictor. The out-of-bag permutation error showed a low ranking of 
importance for modality as a predictor. These results indicate there is no strong influence of 
modality on expansion response in the esophagus.     
 The influence of modality on esophagitis grade was examined with the LASSO NTCP 
modelling analysis. These had similar results as the Random Forests regression modelling 
process, where modality did not show a strong influence as a model predictor for the grade 3 
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esophagitis complication. With the strong correlation of expansion biomarker and toxicity, this 
result should be expected. Both model types were quite similar in performance, as well as the 
most recurring predictors in the iterative model construction process.  
 This work was not without limitations. The dosimetry of proton-based radiation therapy 
is still an active area of research.88-94 For this study we used proton dose calculated from the 
treatment planning system, which can differ from more robust dose calculation methods such 
as Monte Carlo.95-98 This is of particular interest in the normal esophagus and NSCLC treatment 
as the distal end of the proton beam is typically proximal to the esophagus. Further studies 
examining the impact of miscalculation of proton dose and any resultant effect on the 
esophagus would be of interest. Another limitation is that the study patients were treated with 
PSPT. Newer proton radiation treatment techniques, specifically spot-scanning are replacing the 
passively-scattering technique, as the standard treatment where protons are utilized.99-100 
While spot-scanning shows reduced normal tissue dose, it is unknown if this would have any 
effect on response in the normal esophagus. 
 In conclusion, the previously identified highest performing radiation response 
biomarkers were verified with the patient cohort receiving proton therapy. This strengthens the 
conclusions from chapters 3 and 5 on which biomarkers were the most robust. Additionally, 
there is not any significant difference in biomarker response for patients treated with either 
PSPT or IMRT, despite higher dose-volume for the PSPT patients in the expansion analysis. 
Inclusion of modality information did not have an effect on toxicity prediction modelling.   
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Chapter 8 
 
Esophageal Expansion to Identify Patient Radiosensitivity 
 
 
In previous chapters, esophageal expansion was shown to be a robust measure of 
patient-specific radiation-response in the esophagus. It was also shown that the expansion-
response varied patient to patient, even for patients with similar delivered doses. These 
previous results hinted at the possibility of expansion-response as an in-vivo quantification of 
individualized radiosensitivity in the esophagus.  
In this chapter, the utility of the esophageal expansion-response as a patient-specific 
quantification of inherent radiosensitivity was assessed. Study patients were clustered according 
to expansion and corresponding delivered dose to the esophagus to identify subpopulations of 
inherent radiation sensitivity, using Gaussian mixture modelling. This clustering was calculated 
for expansion-response at the week of maximal expansion for a given patient, as well as 
expansion-response toward the end of treatment at approximately fraction 30. Radiosensitive 
patients were classified for the clusters with high expansion and a corresponding lower dose. 
This radiosensitivity tag was used in the toxicity prediction modelling process to improve model 
performance.  
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8.1 Methods and Materials 
8.1.1 Patient Population 
The patient population for this chapter (project 3.3) contains the same patient cohort 
used for the expansion-based analyses from chapter 7 (project 3.2). This was a combination of 
patients treated with IMRT (n=85), and PSPT (n=49), for a total of 134 study patients.  
All patients were selected from the prospective clinical trial at University of Texas-MD Anderson 
Cancer Center for stage III NSCLC, described in previous chapters. Esophagitis scoring was 
conducted in accordance to Common Terminology Criteria for Adverse Events version (CTCAE) 
3.0. Table 8.1 lists the demographics and distribution of maximum esophagitis grades during 
treatment for patients used for the analysis in this chapter. Our study was approved by the 
University of Texas-MD Anderson Cancer Center Institutional Review Board and was compliant 
with HIPAA regulations. 
CT scans were acquired on General Electric Lightspeed Discovery ST or Lightspeed RT16 
(GE Healthcare, Waukesha, WI) or Philips Brilliance 64 (Philips Healthcare, Bothell, WA) CT 
scanners operated at 120 kV. Voxel dimensions were 0.98x0.98x2.50 mm3 in the right-left 
direction, anterior-posterior, and superior-inferior direction, respectively, with a 512×512-pixel 
area. Patient treatment planning and segmentation was conducted using the Pinnacle 
treatment planning system (Phillips Healthcare), with esophageal contours segmented from the 
cricoid cartilage to the gastroesophageal junction, in the axial plane, with Pinnacle version 9.8.  
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Table 8.1: Demographics of study patients (n=134). 
Characteristic Datum 
Median age (range)  
All 66 (38-85) 
Male 66 (43-85) 
Female 65 (38-80) 
Sex  
No. of Males 75 
No. of Females 59 
Histologic findings  
Squamous cell carcinoma 47 
Adenocarcinoma 75 
Large cell carcinoma 5 
Other 7 
Smoking history  
Current smoker 44 
Former smoker 79 
Never smoked 11 
Stage  
IIa 5 
IIb 9 
IIIa 59 
IIIb 56 
IV 5 
Treatment dose, Gy  
74 88 
66 38 
60 8 
Maximum Esophagitis  
    Grade 
 
Grade 0 33 
Grade 2 95 
Grade 3 26 
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8.1.2 Quantification of Expansion-Response  
 The expansion-response for a given patient was quantified as the mean expansion and 
corresponding mean delivered dose, to the subvolume of the esophagus comprised of 9 axial 
slices of the esophagus, centered at the slice location of MaxExp1. Expansion is quantified at 
the week of maximal expansion as well as at the end of treatment, around fraction 30. This 
region of analysis was chosen for two reasons. First, the 9 axial slice region is consistent in size 
for all study patients. Second, the size of analysis region must be large enough to quantify 
uncertainty in dose, yet sufficiently small enough to localize response.  
 Delivered dose was quantified as voxel dose at the time of expansion quantification. 
This can be less than planning dose, especially for analysis examining time of maximum 
expansion, as maximal expansion occurs many fractions before treatment completion for most 
patients, and incorporates a temporal element in the response quantification. The combination 
of expansion value and corresponding delivered dose at the time of maximum expansion is the 
expansion-response for a given patient.  
 
8.1.3 Radiosensitivity Clustering of Patients  
The expansion dose-response quantified at the week of maximal expansion as well as at 
the end of treatment around fraction 30, were clustered separately using multiple clustering 
methods including: Gaussian mixture model using expectation-maximization (GMM-EM), 
Bayesian Gaussian mixture model (Bayesian GMM), and K-Means mixture model (K-Means).  All 
three methods are variations of clustering using Gaussian mixture modelling, which is a process 
of identifying membership of the data to a finite number of unique clusters, based on the 
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assumption that the observed data distribution is a collection of multiple Gaussian distributions. 
These unique underlying Gaussian distributions are representative of the data clusters we seek 
to identify as indicative of patient radiosensitivity.  
The method by which each of the three clustering algorithms derives the Gaussian 
distributions, and thereby data clusters, are different. K-Means clustering is commonly used 
technique where squared Euclidean distance is used as a dissimilarity measure.62,101,102  
Minimization of dissimilarity for data points in a given number of clusters is used to find the 
solution. Gaussian mixture modeling with expectation-maximization is a similar procedure to K-
Means clustering.62 One notable difference between these two methods is that covariance of 
data and probability of a data point belonging to a particular cluster is used to find a solution 
(Expectation). After expectation of a given data point is calculated, maximization calculates 
model parameters based on the means of membership for data in the clusters. This is an 
iterative process that is repeated until convergence is achieved. Bayesian GMM is similar to the 
GMM-EM, with the critical difference that in this method, all parameters are considered random 
variables where the priors are used in the calculation.103   
The underlying premise in utilizing clustering to identify patient sub groups that are 
radiosensitive is that a particular cluster must have a proportionally higher expansion per 
delivered dose than other clusters. Based on the previous assumption, we assume that the 3 
following clusters should be observed based on radiosensitivity: the radiosensitive cluster, 
which has the highest expansion per delivered dose; the radio-insensitive cluster, which has 
high delivered dose, but proportionally lower expansion than the radiosensitive group; and 
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third the radio-normal cluster, which has lower expansion and delivered dose than the two 
other clusters.  
Before clustering was calculated, patients with esophageal subvolume doses of less than 
20 Gy were excluded from the analysis (n=8). This is because there was insufficient dose to 
determine what group of radiation sensitivity these patients would belong. All 8 of these 
excluded patients had grade 0 maximum esophagitis. After clustering the 126 remaining 
patients using the three different techniques, the radiosensitive patient cluster was identified 
and then used in the NTCP modelling process. 
    
8.1.4 LASSO NTCP Modelling and Radiosensitivity 
 In chapters 4 and 7, LASSO penalized logistic regression was utilized as a multivariate 
analysis method. In this chapter, we similarly used LASSO logistic regression to examine if the 
radiosensitivity cluster membership substantially improves esophagitis prediction modelling. 
First, LASSO NTCP models were constructed with the 126 patients that were clustered in a 
repeated cross-validation procedure, for 1000 iterations, which was previously described in 
chapters 4 and 7. To reiterate, predictor variables in the form of dosimetric and clinical factors 
were used as covariates to create NTCP models for ≥ grade 3 esophagitis, according to CTCAE 
version 3.0.  
The same dosimetric and clinical factors described in chapters 4 and 7 were utilized as 
covariates in the models reported in this chapter (Table 8.2). Models were trained and tested on 
separate data in each iteration of the cross-validation procedure. Each iteration used randomly 
drawn training and test sets comprised of 75% and 25% of the study patient population, 
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respectively. Model performance was quantified with Brier scores and AUC from ROC analysis 
on both the training (fit performance) and test (prediction performance) data sets. The 
recurrence of model features was quantified by recording variables in each model, for every 
iteration of the cross-validation procedure.  
 
Table 8.2: Predictor variables used in the NTCP model construction process. 
    Predictor Index Predictor Predictor Index Predictor 
1 Smoking Status 28 LE6025% 
2 Induction Chemotherapy 29 LE5025% 
3 GTV 30 LE4025% 
4 Histology-other 31 LE3025% 
5 Histology-Large Cell 32 LE2025% 
6 Histology-Adenocarcinoma 33 LE1025% 
7 Histology-Squamous Cell 34 V70 
8 Nodal Involvement 35 V65 
9 Stage-IV 36 V60 
10 Stage-IIIB 37 V55 
11 Stage-IIIA 38 V50 
12 Stage-IIB 39 V45 
13 Stage-IIA 40 V40 
14 Tumor Location-Left Lateral 41 V35 
15 
Tumor Location-Right 
Lateral 42 V30 
16 Tumor Location-Left Medial 43 V25 
17 
Tumor Location-Right 
Medial 44 V20 
18 Tumor Location-Left Upper 45 V15 
19 Tumor Location-Right Upper 46 V10 
20 Gender 47 Mean Esophagus Dose 
21 Age 48 Max Esophagus Dose 
22 LE60100% 49 Prescription Dose 
23 LE50100% 50 Radiosensitivity Tag 
24 LE40100%  
25 LE30100%  
26 LE20100%  
27 LE10100%  
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 The model construction procedure was then repeated with radiosensitivity as an 
additional covariate. The previously described clustering technique was used to identify patients 
that had proportionally higher expansion-response then other study patients, and this 
information was quantified as a dichotomous variable (1 for radiosensitive patient, 0 otherwise), 
in the LASSO NTCP model construction process. Model performance was assessed and 
recurring model predictors were cataloged for every iteration of the model construction 
process. The results of both model construction scenarios (with and without the radiosensitivity 
predictor) were compared. 
 
8.1.5 Analysis of IMRT versus Protons for Radiosensitive Patients 
 As will be shown in the results section, clustering of expansion-response can identify 
radiosensitive patients. This information was used to reanalyze patients that were radiosensitive 
to determine if radiation modality affects expansion-response for this subset of patients. As will 
be shown later in the result section, Bayesian GMM based clustering leads to the highest 
predictive performance in multivariate modelling, and thus will be the cluster method utilized 
for this modality analysis. Expansion-response was analyzed at the end of treatment, to keep 
time of analysis approximately constant. 
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8.2 Results 
8.2.1 Expansion-Response  
The expansion-response for a given patient’s week of maximal expansion, for all 134 
study patients, is shown in Figure 8.1. The expansion-response towards the end of treatment is 
shown in Figure 8.2. For both time points, an overall trend of increasing dose and toxicity 
severity is observed, but this has high patient-to-patient variability. Additionally, the expansion 
per delivered dose is quite variable. The distribution of expansion in 10 Gy dose partitions, from 
20 Gy up to 70 Gy, is shown in Figure 8.3, for both time points of expansion-response. Here a 
high variance of expansion is observed for patients with similar doses. The standard deviation 
of expansion in a given dose partition is also shown, with a standard deviation of expansion 
value of 30% being typical.  
The 8 pateints excluded from the clustering and NTCP analyses can be observed in 
Figures 8.1 and 8.2 as the patients with mean subvolume doses under 20 Gy. The resultant 
clustering from each of the three methods at the two different expansion-response time points  
is shown in Figure 8.4. The radiosensitive cluster is red, the radio-normal cluster is blue, and the 
radio-insensitive cluster is black, in each of the three clustering methods. For all three methods, 
the assigned clusters’ radiation sensitivity met the necessary assumptions of expansion-reponse 
described in the methods section. 
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Figure 8.1: Plot of expansion-response at patient’s week of maximal expansion in the analyzed 
subvolume of the esophagus for 134 study patients. Patient markers denoted maximum 
esophagitis grade during treatment. 
 
 
Figure 8.2: Plot of expansion-response at the end of radiation therapy (approximately fraction 
30) in the analyzed subvolume of the esophagus for 134 study patients. Patient markers 
denoted maximum esophagitis grade during treatment. 
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Figure 8.3: Boxplot of the distribution of mean subvolume esophageal expansion grouped 
according to mean subvolume doses of 20 to 30 Gy, 30 to 40 Gy, 50 to 60 Gy, and 60 to 70 Gy, 
for 126 study patients, for expansion-response quantified at the patient’s week of maximal 
expansion (A) and at treatment fraction 30 (B). The standard deviation of expansion in each 
dose group is shown above each box. The edges of the box represent the quartile values of 
expansion, with the red line within each box representing that groups median expansion value. 
The range of values is represented by the black whiskers and the red ‘+’ denotes outliers 
(values beyond 1.5 times the interquartile range from the edge of the box).  
 
 
 8.2.1 Radiosensitivity Clustering  
 Distributions of cluster membership, as well as esophagitis grade within each cluster is 
given in Table 8.3 for expansion-response quantified for the week of maximal expansion, and in 
Table 8.4 for expansion-response quantified at the end of radiation therapy. For all three 
clustering methods, no grade 0 patients were found in the radiosensitive cluster, but most 
grade 3 patients were. However, many grade 2 patients were also found in the radiosensitive 
cluster. GMM-EM and K-Means showed the most similarity in patient cluster membership, with 
Bayesian GMM showing consistency with the other two methods. The radio-insensitive (black) 
cluster contained the most patients regardless of clustering method, and all 3 esophagitis grade 
endpoints were observed within this cluster. 
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Figure 8.4: Plots of patient clustering of expansion-response measured at the week of a 
patient’s maximal expansion by Bayesian Gaussian mixture model (A), for cluster size of 3, K-
Means clustering (B) for cluster size of 3, and Gaussian mixture model using expectation-
maximization clustering (C) for cluster size of 3, and expansion-response measured near 
treatment fraction 30 by Bayesian Gaussian mixture model (D), for cluster size of 3, K-Means 
clustering (E) for cluster size of 3, and Gaussian mixture model using expectation-maximization 
clustering (F) for cluster size of 3, for 126 patients in all scenarios. Cluster membership is 
denoted by color of expansion-response data point for a given patient. 
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Table 8.3: Characteristics of clustering membership for Bayesian GMM, K-Means, and GMM-EM 
clustering methods for expansion-response at the week of maximal expansion for the 126 
patients analyzed in the cluster analysis. 
Bayesian GMM 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 14 14 28 22.2 
Blue 11 20 0 31 24.6 
Black 14 41 12 67 53.2 
n = 25 75 26 126 100.0       
K-Means 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 16 13 29 23.0 
Blue 11 25 6 42 33.3 
Black 14 34 7 55 43.7 
n = 25 75 26 126 100.0       
GMM-EM 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 18 14 32 25.4 
Blue 6 22 4 32 25.4 
Black 19 35 8 62 49.2 
n = 25 75 26 126 100.0 
 
8.2.3 LASSO NTCP Modelling and Modality 
 The LASSO NTCP model construction procedure had similar distributions of recurring 
model predictors, even for NTCP models not using radiosensitivity as a predictor variable. These 
results are shown in Figures 8.5 and 8.6, for expansion-response at the week of maximal 
expansion, and in Figures 8.7 and 8.8, for expansion-response calculated at the end of radiation 
therapy. For models constructed with the radiosensitivity variable, this predictor was the most 
recurring variable and was chosen in over 99% of the 1000 iterations of model construction. 
Mean esophageal dose was the second most recurring predictor in the radiosensitivity 
information inclusive models, as well as the most recurring predictor in the models not 
including the radiosensitivity information.  
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Table 8.4: Characteristics of clustering membership for Bayesian GMM, K-Means, and GMM-EM 
clustering methods for expansion-response at the end of radiation therapy for the 126 patients 
analyzed in the cluster analysis. 
Bayesian GMM 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 29 21 50 39.7 
Blue 7 8 0 15 11.9 
Black 18 38 5 61 48.4 
n = 25 75 26 126 100.0 
      
K-Means 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 19 20 39 31.0 
Blue 8 7 0 18 14.3 
Black 17 46 6 69 53.8 
n = 25 75 26 126 100.0 
      
GMM-EM 
Cluster Grade 0 Grade 2 Grade 3 n = % of Cluster 
Red 0 37 23 60 47.6 
Blue 7 8 0 15 11.9 
Black 18 30 3 51 40.5 
n = 25 75 26 126 100.0 
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Figure 8.5: Bar charts of the occurrence of predictors for all 1000 iterations of the LASSO 
logistic regression NTCP modelling construction process. Models using the radiosensitive tag 
variable from Bayesian GMM clustering of expansion-response at the week of maximal 
expansion are shown in the left bar chart, and models created without the radiosensitivity 
predictor is shown in the right bar chart. The predictor index number identifies the specific 
predictor variable from Table 8.2.  
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Figure 8.6: Bar charts of the occurrence of predictors for all 1000 iterations of the LASSO 
logistic regression NTCP modelling construction process. Models using the radiosensitive tag 
variable calculated using expansion-response at the week of maximal expansion and from 
GMM-EM clustering are shown in the left bar chart, and from K-Means clustering are shown in 
the right bar chart, respectively. The predictor index number identifies the specific predictor 
variable from Table 8.2. 
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Figure 8.7: Bar charts of the occurrence of predictors for all 1000 iterations of the LASSO 
logistic regression NTCP modelling construction process. Models using the radiosensitive tag 
variable from Bayesian GMM clustering of expansion-response at the end of radiation therapy 
are shown in the left bar chart. The predictor index number identifies the specific predictor 
variable from Table 8.2. 
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Figure 8.8: Bar charts of the occurrence of predictors for all 1000 iterations of the LASSO 
logistic regression NTCP modelling construction process. Models using the radiosensitive tag 
variable calculated using expansion-response at the end of radiation therapy and from GMM-
EM clustering are shown in the left bar chart, and from K-Means clustering are shown in the 
right bar chart, respectively. The predictor index number identifies the specific predictor 
variable from Table 8.2. 
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The NTCP model performance for all four investigated scenarios is summarized for 
expansion-response at the week of maximal expansion in Table 8.5, as well as the expansion-
response at the end of radiation therapy in Table 8.6. All three model types using clustering to 
identify radiosensitive patients outperform modelling without radiosensitivity information (first 
row of Table 8.5). The training and predictive performance of models using clustering have 
significantly higher AUCTraining and AUCTest (according to a paired T-test on AUC values for each 
corresponding iteration of cross-validation, p<0.05). Both types of Brier scores were optimal 
(lower value) for the three clustering/radiosensitivity model types compared to no 
radiosensitivity information models. The models using the Bayesian GMM clustering had the 
highest performance of any of the four model types.  
 
Table 8.5: Results of the LASSO logistic regression NTCP model construction process using 
multiple clustering methods to identify radiosensitive patients, from expansion-response 
quantified at the week of maximal expansion, for a total of 126 study patients. The highest 
recurring predictors from all 1000 iterations of the model construction process are listed from 
highest to lowest recurring. Standard deviation of AUC values are listed in parentheses. 
Model AUCTraining (S.D.) AUCTest (S.D.) Brier Score Scaled Brier (%) 
No Clustering 0.842 (±0.065) 0.693 (±0.099) 0.175 (±0.020) 18.2 (±12.0) 
Bayes Clustering 0.903 (±0.043) 0.790 (±0.090) 0.141 (±0.021) 7.8 (±11.2) 
GMM-EM Clustering 0.893 (±0.051) 0.756 (±0.092) 0.150 (±0.021) 13.0 (±12.4) 
K-Means Clustering 0.907 (±0.055) 0.763 (±0.094) 0.148 (±0.022) 14.3 (±12.9) 
Model Top Recurring Predictors 
No Clustering MED, LE50Gy100%, Left Medial, LE60Gy100%, Smoking Status  
Bayes Clustering 
RS Tag, MED, LE60Gy100%, Left Medial, Smoking Status  
GMM-EM Clustering RS Tag, MED, LE60Gy100%, Smoking Status, Left Medial, Age 
K-Means Clustering RS Tag, MED, LE60Gy100%, Smoking Status, Left Medial, Age 
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Table 8.6: Results of the LASSO logistic regression NTCP model construction process using 
multiple clustering methods to identify radiosensitive patients, from expansion-response 
quantified at the end of radiation therapy, for a total of 126 study patients. The highest 
recurring predictors from all 1000 iterations of the model construction process are listed from 
highest to lowest recurring. Standard deviation of AUC values are listed in parentheses. 
Model AUCTraining (S.D.) AUCPrediction (S.D.) Brier Score Scaled Brier (%) 
Bayes Clustering 
0.906 (±0.046) 0.792 (±0.090) 0.140 (±0.020) 14.6 (±11.9) 
GMM-EM Clustering 
0.900 (±0.048) 0.773 (±0.089) 0.144 (±0.020) 15.3 (±11.7) 
K-Means Clustering 
0.885 (±0.053) 0.753 (±0.094) 0.151 (±0.019) 12.1 (±11.2) 
Model Top Recurring Predictors 
Bayes Clustering RS Tag, MED, LE60Gy100%, Left Medial, Smoking Status  
GMM-EM Clustering RS Tag, MED, LE60Gy100%, Smoking Status, Left Medial, Age 
K-Means Clustering RS Tag, MED, LE60Gy100%, Smoking Status, Left Medial, Age 
 
 
8.2.4 Modality and Radiosensitivity 
 Patients clustered into the radiosensitive group using the Bayesian GMM did not show a 
significant difference in expansion-response.  Figure 8.9a shows the expansion-response of 
these patients and their corresponding modality. A boxplot of the distribution of subvolume 
expansion is shown in Figure 8.9b. Kruskal-Wallis ANOVA determined a p-value of 0.09, which is 
not statistically significant (p<0.05). 
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Figure 8.9: (A) Expansion-response at the end of radiation therapy for radiosensitive clustered 
patients according to Bayesian GMM and grouped according to modality. (B) Boxplot of 
subvolume expansion for patients in (A). 
 
 
8.3 Chapter Discussion 
 In this chapter, three different clustering methods (K-Means, Gaussian mixture model 
using expectation-maximization, and Gaussian mixture model using Bayesian methods) were 
utilized to identify patients’ inherent radiosensitivity from their respective expansion-response. 
The full expansion patient dataset which was utilized in chapter 7 is used in this chapter. 
Clustering was carried out for expansion-response at the week of a given patient’s maximal 
expansion, as well as expansion-response towards the end of treatment with the expansion 
quantification closest to fraction 30. This information was then used to label patients as either 
radiosensitive or not radiosensitive. This label was then converted to a dichotomous variable 
and used in the NTCP modelling process in an attempt to improve esophagitis prediction 
models. In a similar analysis to chapter 4 and chapter 7, LASSO logistic regression was utilized 
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in a repeated cross-validation procedure to test model performance when including this 
radiosensitive variable in the model construction process. 
 The expansion-response of these patients was highly variable for both time points of 
expansion-response quantification. For similar subvolume doses, many patients had vastly 
different amounts of expansion, as well as esophagitis grade.  This shows the pitfall of toxicity 
prediction modelling without accounting for inherent radiation sensitivity, where variability of 
patients’ response outweighs the study population’s average observed response. Additionally, 
in chapters 6 and 7 we did not observe expansion being influenced from either dose-geometry 
or modality, respectively. The variability of response for patients with similar delivered dose 
may render detecting such effects arduous if patient radiosensitivity is not considered. A 
reanalysis of the question of modality influencing expansion was carried out for the patients 
within the radiosensitive cluster. This analysis confirmed our previous findings that radiation 
modality, in the form of IMRT and proton therapy, does not influence expansion response. 
 The results of the different clustering methods were consistent between the three 
techniques. Radiosensitive clusters were observed in all three methods that met the assumed 
trend of proportionally higher response for a lower delivered dose, compared to the other two 
cluster types.  The other two clusters met their assumed trends, with a low response with a 
corresponding low delivered dose for the radio-normal cluster type, and a lower response with 
a corresponding higher dose, compared to the radiosensitive cluster, for the radio-insensitive 
cluster type. These were consistent regardless of clustering method or for time points of 
expansion-response quantification.  
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 NTCP models using any of the three clustering methods to create radiosensitivity 
predictor variables outperformed NTCP models not utilizing radiosensitivity information, for a 
grade 3 maximum esophagitis endpoint. The Bayesian GMM-based radiosensitivity models had 
the highest overall performance out of the four modelling scenarios. GMM-EM and K-Means 
radiosensitivity derived models still outperformed models without radiosensitivity information. 
The performance metrics are even more impressive, as 8 low-dose, low-response, and 
asymptomatic patients were excluded from the model construction process. In typical 
modelling situations, these types of patients are easily classified by the model and contribute to 
higher model performance, which would be reflected in any quantification of predictive ability. 
By not including these patients, the modelling situation is more difficult to classify esophagitis, 
and this translates into a more robust model. 
 Model performance for the expansion-response at the end of radiation therapy was 
similar to modelling using the expansion-response at the week of maximal expansion. This is a 
very impactful result, as simply quantifying expansion-response towards the end of treatment 
allows for direct application in outcome assessment. This lends to the potential for expansion-
response quantification at the end of therapy, in conjunction with the clustering methodology, 
to be used as a framework to objectively assess outcomes and quantify variability of inherent 
radiation-response within a study cohort. More on this will be described in the project 
discussion in chapter 9. 
 This work was not without limitations. The clustering process is unsupervised in terms of 
esophagitis outcome, and therefore requires some assumptions for interpretation. As described 
in the methods section, the cluster assignment of radiosensitivity was determined based on the 
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assumptions of relative expansion-response within the study population. It is vital to validate 
these findings on an external dataset, as it would be interesting to see if cluster assignment and 
shape would change with new patient data. Another limitation was that the radiosensitivity 
information was only used dichotomously (radiosensitive or not radiosensitive). It would be of 
interest to analyze the utility of not just the radiosensitive clusters, but also patients labelled as 
radio-normal and radio-insensitive. The radio-insensitive cluster in particular would be of 
interest in dose-escalation studies. 
 In conclusion, clustering techniques can be applied to the expansion-response 
mechanism to determine patient radiosensitivity in the esophagus. This radiosensitivity 
information can be used in the NTCP modelling process to improve toxicity prediction 
performance. Patient inherent radiosensitivity can be assessed towards the end of radiation 
therapy. These results should be verified on an external dataset. 
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Chapter 9 
 
Discussion 
 
 
9.1 Summary of Findings 
In this dissertation, novel imaging biomarkers of physiological radiation-response were 
derived, validated, and applied to advance the knowledge of dose-response and radiation 
injury in the esophagus. The previous paradigm for understanding dose-response in the 
esophagus, in our context of a side effect from the treatment of lung malignancy, can be 
summarized as delivering radiation for the treatment of non-small-cell lung cancer, which 
induces normal tissue toxicity quantified by subjective physician grading criteria. The 
subjectivity in quantifying response, together with the lack of ability to localize response to 
precise sub-regions of the esophagus, served as the impetus for this PhD work. A summary of 
the specific aims, hypotheses, projects, and results, can be found in Table 9.1. 
The work in chapter 3 showed that esophageal expansion can be calculated from 
planning and corresponding intra-treatment 4DCT scans to quantify relative, localized volume 
change in the esophagus. Metrics of esophageal expansion were derived as objective imaging 
biomarkers of radiation-response in the esophagus. We then showed these imaging biomarkers 
were highly correlated to esophageal toxicity. It was also shown in this chapter that expansion 
peaks in the last few weeks of treatment, indicating optimal assessment of the expansion 
radiation-response towards the conclusion of radiation therapy.   
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Table 9.1: Summary of dissertation specific aims, hypotheses, and results from individual 
projects. 
Specific Aim Hypothesis Projects Results 
SA1: Analysis of CT-based 
Esophageal Expansion to 
Quantify Radiation Response 
in the esophagus during 
radiation therapy 
CT-based esophageal 
expansion is a biomarker of 
radiation response in the 
esophagus and can be used to 
improve outcome modelling of 
radiation-induced esophagitis 
Project 1.1 
Expansion is a radiation 
response biomarker and highly 
correlated to toxicity 
Project 1.2 
NTCP models with expansion 
biomarker as endpoint 
outperform traditional grade 
endpoint NTCP models 
SA2: Analysis of FDG-PET to 
Quantify Esophageal 
Radiation Response in the 
esophagus during radiation 
therapy 
FDG-PET uptake is a 
biomarker of radiation response 
in the esophagus and can be 
used to predict symptom 
progression during radiation 
therapy 
Project 2.1 
Normalized uptake is a 
radiation response biomarker 
and highly correlated to 
toxicity 
Project 2.2 
Normalized uptake can predict 
toxicity progression during 
radiation therapy 
SA3: Analysis of Esophageal 
Dose-Response Using 
Radiation Response 
Biomarkers 
Esophageal expansion will 
identify if dose-geometry or 
radiation type contribute to 
radiation injury in the 
esophagus, and that expansion 
can be used to quantify patient-
specific radiosensitivity 
Project 3.3 
Dose-geometry does not have 
a detectable influence on 
expansion  
Project 3.2 
IMRT and Proton therapy do 
not have substantial 
differences in expansion 
Project 3.3 
Expansion can identify 
radiosensitive patients and this 
knowledge can improve 
toxicity prediction models 
 
Next, the two expansion-based biomarkers most highly correlated to maximum 
treatment toxicity, MaxExp1 and LenExp30%, were shown to be robust endpoints in the toxicity 
prediction modelling process (chapter 4). Three different modelling construction techniques 
(forward, stepwise logistic regression; LASSO penalized logistic regression; and Random Forests 
classification) all showed a higher predictive performance for models created with either of the 
two expansion-based biomarker endpoints, compared to models created with esophagitis 
grade as the model endpoint. Furthermore, the repeated cross-validation procedure effectively 
created 1000 individual prediction models, though created from a similar distribution of 
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samples, and showed the robustness of this result was not due to random partition of the 
model training data.  
The other biomarker type, based on normalized FDG uptake, was studied in chapter 5. 
FDG uptake from a single mid-treatment scan was normalized to the low dose region of an 
individual patient’s esophagus, providing a patient-specific, radiation-response quantification. 
Metrics of normalized uptake were derived in a similar fashion as the expansion-based metrics, 
with many shown to be highly correlated to esophageal toxicity. Interestingly, the two highest 
toxicity-correlated FDG-based biomarkers, nSUVAxMax1 and nSUVLen40%, were similar in form to 
the highest performing expansion-based biomarkers (MaxExp1 and LenExp30%). This is an 
intuitive finding, as swelling and inflammation are related physiological processes.  
FDG uptake was also shown to be predictive of toxicity progression for patients 
asymptomatic at the time of the FDG-PET scan. The magnitude of the FDG-based biomarker 
could predict which patients would develop esophagitis. This was not information obtainable 
from the radiation dose, indicating unique and clinically beneficial information in the FDG-PET 
study for the purpose of understanding radiation-response in the esophagus.   
 Chapter 6 was the first of three chapters addressing specific aim 3, and examined 
whether or not dose-geometry influences expansion radiation-response. The primary interest of 
this project was to investigate if particular dose-geometries, particularly reducing cross-
sectional coverage of dose across the axial plane of the esophagus, allows for partial sparing 
and a reduction in response of the esophagus. Utilizing the expansion biomarker allowed 
precise quantification of localized dose-response, not previously possible. It was shown that 
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there was no clear trend between the coverage of dose across the cross-sectional area of a 
given slice of the esophagus and expansion-response. 
 Next, patients treated with either IMRT or Proton therapy were analyzed to determine if 
modality had a strong influence on esophageal radiation-response (chapter 7). FDG-based 
biomarkers did not show any significant difference in biomarker value when grouped by 
treatment modality and toxicity outcome.  Analysis of biomarker magnitude for comparable 
equivalent uniform dose did not show a dependence on radiation therapy modality. Analysis of 
expansion-based biomarker grouped according to treatment modality and esophagitis grade 
outcome did show a lower response for patients treated with proton therapy compared to 
IMRT, for patients who had grade 3 esophagitis. However, removing the outliers in the IMRT 
group then showed no significant difference between response and modality. Furthermore, the 
proton patients that become grade 3 esophagitis during treatment would still be classified as 
high-response patients when using the MaxExp1 ≥ 50% threshold criterion. Analysis of 
expansion biomarker value as a function of equivalent uniform dose did not show a difference 
between treatment modalities. When examined using multivariate modelling, modality was not 
influential in either Random Forests regression of MaxExp1 value, or LASSO logistic regression 
classification of the ≥ grade 3 esophagitis outcome, despite strong prediction performance for 
models in both scenarios.  
 In chapter 8, it was shown that esophageal expansion can quantify patient 
radiosensitivity, and this result improved esophagitis prediction modelling. Clustering patients 
based on either their maximum expansion and corresponding delivered dose to the sub-
volume of the esophagus with the highest response (expansion), or expansion-response and 
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corresponding dose quantified at the end of radiation therapy, showed patients with similar 
doses can have markedly different response, as well as toxicity. This highlights a paramount 
concern that previous dose-response studies could not overcome: the inherent variability of an 
individual patient’s radiosensitivity. By identifying the patients in the radiosensitive cluster, we 
were able to substantially improve esophagitis prediction modelling by including this 
radiosensitivity information in the model. By being able to quantify the radiosensitivity at a 
single time point towards the completion of therapy lends itself to be an impactful tool for 
outcome assessment. When put into context with projects 3.1 and 3.2, the results of the 
radiosensitivity analysis in chapter 8, shows that patient radiosensitivity is a dominant variable 
in esophagus dose-response. Furthermore, future studies of dose-response in the esophagus 
need to consider patient variation in radiosensitivity. Otherwise, any resulting trend, association, 
or lack of either, can be overshadowed by the distribution of patient radiosensitivity within the 
study population. Additionally, this result of the degree of variability in radiosensitivity leads to 
many future directions, which will be discussed in the following sections. 
 
9.2 Limitations and Future Work 
 While overall there are many impactful findings from this work, there exists some 
limitations. This patient cohort was unique in that patients had weekly 4DCT acquisitions during 
treatment, which is required to quantify esophageal expansion. Similarly, many patients also 
had a single mid-treatment FDG-PET/CT scan in the treatment position with immobilization, 
which is necessary to calculate the FDG-based biomarkers. In both types of imaging, this is not 
commonplace in radiation oncology clinics.  
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While this work suggests clinical benefit to acquire either type of scan to quantify 
expansion or FDG uptake, the logistics and cost are prohibitive in the typical clinical setting. 
This reality restricts the clinical application of imaging biomarker application to 
academic/research hospitals until either the additional benefit of these imaging acquisitions is 
increased or the cost of imaging is reduced. However, image guidance is being utilized at an 
increasing pace in radiation oncology. In the case of FDG-PET, the imaging dose and cost are 
even more prohibitive than 4DCT. 
  Another limitation in this work is the dosimetry, particularly for patients treated with 
proton therapy. Dose calculations for proton treatments are still an active area of research, with 
uncertainty in dose at the distal end of the proton beam. This is of particular concern in dose to 
the normal esophagus, as NSCLC tumor location is typically such that the distal end of the 
proton beam lies near the esophagus. It would be interesting to note any difference in proton 
dose calculated using more robust methods, such as Monte Carlo simulations, to the treatment 
planning software calculated dose in this work. Furthermore, it would be of interest if any 
presumed differences in dose have an impact on dose-response in the esophagus. 
Toxicity prediction modelling was a common application in many stages of this work. 
However, one limitation is the fact we did not have an external dataset to validate the 
modelling results. Unfortunately, the lack of suitable external validation datasets is more often 
than not the reality in many novel toxicity prediction studies. However, cross-validation is a 
suitable technique to approximate model performance in lieu of an external validation dataset. 
It would of interest to validate these results as image guidance is utilized in radiation oncology 
at an ever increasing pace.  
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 Another limitation that is inherent in outcome assessment studies is the fact that we are 
using retrospective data from patients already affected by the toxicity of interest. However, one 
very impactful result from this could seek to shift this paradigm, which we describe in the next 
section. 
 
9.3 Application to Clinical Trials 
In the age of personalized medicine, the uniqueness of patients is being quantified to 
tailor treatment. Furthermore, radiogenomics and radiomics are playing their part in this 
schema by attempting to identify pre-treatment biomarkers. This is certainly the case with 
radiosensitivity and its relationship with normal tissue toxicity. Validating pre-treatment 
biomarkers can be arduous when toxicity grade is the endpoint used for validation. As 
mentioned throughout this work, esophagitis grade is subjective. 
As we have shown in chapter 8, radiosensitivity has a profound impact on radiation-
response and toxicity, such that patients of similar dose can have markedly different response. 
From these facts raises an important question: how can we validate pre-treatment biomarkers, 
particularly in the case of toxicity given the subjective outcomes associated with grading 
criteria? The use of either of the in-vivo imaging biomarkers investigated in this work can serve 
this crucial purpose. 
By using expansion and/or FDG-based imaging biomarkers we can potentially validate 
(or invalidate) pre-treatment biomarkers of interest in a prospective clinical trial. By quantifying 
expansion and/or FDG-uptake in the esophagus towards completion of radiation therapy, along 
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with the corresponding esophagus dose, any pre-treatment biomarker of radiosensitivity in the 
esophagus can potentially be validated, as illustrated in Figure 9.1. 
 
 
Figure 9.1: Application of expansion or FDG-based imaging biomarker to validate pre-
treatment biomarker. 
 
While the most logical application of expansion or FDG-based imaging biomarkers is for 
the validation of pre-treatment radiosensitivity and toxicity biomarkers, this framework could 
potentially be applied to other scenarios. For example, radioprotectors could also be validated 
in a similar manner for protection of the esophagus. Another example would be escalation/de-
escalation of radiation dose and its potential impact on toxicity. This framework could identify 
patient-specific response, with consideration to inherent radiation sensitivity. Furthermore, this 
validation framework could be applied in any scenario that involves comparison of two 
treatment modalities or techniques, where esophageal response is a concern. 
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9.4 Conclusions 
In conclusion, the individual projects in this work collectively addressed and supported 
the central hypothesis that esophageal expansion as quantified from 4DCT, and normalized 
uptake quantified from FDG-PET imaging, are imaging biomarkers of radiation-response in the 
esophagus that improve the understanding of esophageal radiation injury. The overall objective 
of this work was to obtain a deeper understanding of dose-response in the esophagus, with the 
long term goal of increasing treatment outcome and improving patient quality of life. This 
further understanding of esophageal dose-response included knowing what role, if any, dose-
geometry, radiation type, and inherent patient radiosensitivity, can have on response. Probing 
these specific potential influences on radiation-response was not possible without the use of 
esophageal expansion or FDG-based biomarkers. The utilization of two different imaging 
biomarker types as radiation-response metrics, sought to reduce the uncertainty in quantifying 
response as a symptom grade, as well as provide spatial information of the extent of response 
in the esophagus.    
 Chapters 3 and 4 showed expansion is a radiation-response biomarker that can quantify 
toxicity and improve esophagitis prediction modelling, confirming the hypothesis of Specific 
Aim 1. Chapter 5 showed FDG-uptake to be an esophageal radiation-response biomarker as 
well, that can predict symptom progression during radiation therapy, thereby confirming the 
hypothesis of Specific Aim 2. The influences of dose-geometry and modality on expansion were 
shown to be non-existent in chapters 6 and 7, respectively. Chapter 8 showed expansion and 
corresponding dose can quantify patient radiosensitivity, and together with the findings from 
150 
 
chapter 6 and 7 confirm the hypothesis of Specific Aim 3 that expansion can identify what 
contributes to radiation injury in the esophagus. 
Collectively, these findings show the benefit of expansion and FDG-uptake as in-vivo 
radiation-response imaging biomarkers that can be utilized to understand and thereby prevent 
radiation injury in the esophagus.  
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